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1 Introduction 
1.1 The Hepatitis C Virus (HCV) infection 
About 150 million people worldwide are chronically HCV infected and 3-4 million 
people are newly infected every year (WHO 2013). After an incubation period of 6 to 
8 weeks mild liver inflammation occurs, however, 75% of infections remain 
asymptomatic. Approximately 80% of infected individuals proceed to develop chronic 
HCV infection, characterized by HCV specific antibodies and viral ribonucleic acid 
(RNA) in their blood. 10% to 20% of chronically HCV infected individuals develop 
liver cirrhosis and about 4% of these develop hepatocellular carcinoma, making HCV 
the major cause of liver transplantations in western industrial countries (Brown 2005). 
About 20% of infected individuals spontaneously resolve HCV infection. Viral RNA 
becomes undetectable in the blood of these individuals, while HCV specific 
antibodies remain detectable and serve as a marker for previous HCV infection.  
 
Intervention strategies to prevent HCV transmissions in high-risk groups showed only 
limited success and prophylactic vaccination against HCV is not available to date. 
Therefore, antiviral therapy is currently the only means to fight HCV. Sustained viral 
response and clearance of HCV-RNA from patients with chronic HCV infection can 
be achieved by therapy with pegylated interferon-α (IFN-α) in combination with 
Ribavirin. However, overall success rates are about 50% and strongly vary between 
HCV genotypes. Novel drugs directly acting against HCV (DAAs) have been recently 
approved for therapy and will further enhance the sustained response rates. 
However, the enormous costs of these novel treatment options will preclude their 
widespread use in countries with limited public health resources. 
1.2 The HCV virion 
The Hepatitis C Virus is a positive-stranded RNA virus and belongs to the family of 
Flaviviridae together with yellow fever virus and dengue virus being other prominent 
members of this family. Together with the recently identified non-primate, rodent and 
bat hepaciviruses (NPHV (Kapoor et al. 2011), RHV (Kapoor et al. 2013) and 
BHV(Quan et al. 2013)) they are grouped into the Hepacivirus genus. 
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Infectious enveloped HCV virions are 50 to 80 nm in diameter. E1 E2 glycoprotein 
heterodimers are embedded in the lipid bilayer surrounding the  nalyser din , 
consisting of core proteins and the RNA genome (Gastaminza et al. 2010) (Figure 
1.1). HCV virions, existing as lipo-viro-particles (LVPs), are not icosahedral, and 
because of their association with low-density and very-low-density lipoproteins (LDL 
and VLDL) in the infected host (Andre et al. 2002; Merz et al. 2011), they are 
pleomorphic with heterogeneous and low density, which varies depending on growth 
conditions (Lindenbach et al. 2006).  
 
 
 
Figure 1.1: HCV virion. 
Schematic drawing of an HCV virion. ( Modified from http://viralzone.expasy.org). 
 
1.3 HCV genome and genome organization  
HCV contains a single-stranded, positive-sense RNA molecule, 9.6 kilo bases (kb) in 
length coding for one open reading frame (ORF) comprising approximately 3000 
amino acids (aa) (Bartenschlager et al. 1993). Translation produces one large 
polyprotein which is cleaved by host and viral proteases into ten viral proteins: core, 
E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B. Unlike Flavi- and 
Pestiviruses, HCV RNA has no cap-structure at its 5‟ end (Figure 1.2).  The ORF is 
flanked by the 5‟ and 3‟ untranslated regions (UTRs). The 5‟-UTR is a well-conserved 
341 nucleotide sequence element that precedes the internal ribosome entry site 
(IRES) mediating translation of the polyprotein (Tsukiyama-Kohara et al. 1992). The 
E1-E2 dimer
Capsid protein
Genomic RNA
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approximately 200 nucleotides long 3‟-UTR is located downstream of the coding 
region. It can be divided into 3 parts (Hsu et al. 2003): The stop codon of the ORF is 
followed by a variable region ( nalyse. 40 nucleotides), a poly-uracil track of 20 to 90 
nucleotides and a highly conserved sequence of 98 nucleotides, which is essential 
for replication (Kolykhalov et al. 1996; Yanagi et al. 1999).  
 
 
Figure 1.2: HCV genome, polyprotein and proteins. 
The 9.6 kb positive-strand RNA genome is schematically depicted at the top. IRES-mediated translation yields a 
polyprotein precursor that is processed into the mature structural and non-structural proteins. Amino acid 
numbers are shown above each protein. Solid diamonds denote cleavage sites of the HCV polyprotein precursor 
by the endoplasmic reticulum (ER) signal peptidase. The open diamond indicates further C-terminal processing of 
the core protein by signal peptide peptidase. Arrows indicate cleavages by the HCV NS2–3 and NS3–4A 
proteases. Dots in E1 and E2 indicate the glycosylation of the envelope (Modified from (Moradpour et al. 2007)). 
 
1.4   The HCV virus life cycle 
The HCV life cycle is a complex process involving many cellular and host proteins, 
recently reviewed by Scheel et al. (Scheel et al. 2013). An overview over viral entry 
and uncoating, translation and polyprotein processing, HCV RNA replication as well 
as virus assembly and release is given in the following.  
1.4.1 Entry and uncoating 
A growing number of host proteins have been identified to be involved in successful 
entry of HCV into hepatocytes. Initial low affinity cell binding is thought be mediated 
by the LDL receptor and glycosaminoglycans (Agnello et al. 1999; Barth et al. 2003), 
core proteaseenvelope
glycoproteins
serine protease, 
helicase
RNA-dependent  RNA 
polymerase
Polyprotein processing
IRES-mediated translation
Polyprotein
Protein
Genome 
membranous 
web  formation
serine protease
cofactor
phosphoprotein,
ER binding  
5‟ UTR and IRIS 5‟ UTR
9.6 kb
1 192 384 747 810 1027 1658 1712 1973 2421 3011
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before E1-E2 interacts with the co-receptors scavenger receptor class B type I (SR-
BI) and CD81 (Pileri et al. 1998; Scarselli et al. 2002). Claudin-1 (CLDN1) and 
Occludin (OCLN) are proteins typically found in tight junctions and are also required 
for HCV entry (Evans et al. 2007; Ploss et al. 2009), possibly causing HCV virions to 
translocate to tight junctions (Figure 1.4). Epidermal growth factor receptor (EGFR) 
and ephrin receptor type A2 are believed to further modulate CD81 and CLDN1 
interaction (Lupberger et al. 2011). Uptake occurs via clathrin-mediated endocytosis 
(Blanchard et al. 2006). E2 is believed to interact with CD81 (Sharma et al. 2011) and 
was predicted to be a class II fusion protein activated by low pH in the endosome. 
These processes lead to the release of the viral genome into the cytoplasm where 
primary translation can occur (Figure 1.3 (a), (b)). Direct cell-to-cell transmission 
probably also occurs in the liver.  
1.4.2 Translation and polyprotein processing  
The HCV genome is highly structured with essential RNA regulatory elements in the 
5‟ and 3‟ UTRs as well as in the coding region (Gottwein et al. 2008). The IRES 
located in the HCV 5‟ UTR initiates Endoplasmatic reticulum (ER)-associated 
translation  (Hoffman et al. 2011),resulting in a polyprotein that is co- and post-
transcriptionally cleaved by cellular proteases (signalase and signal peptide 
peptidase) and the viral NS2-NS3 and NS3-NS4A protease to release the 10 HCV 
proteins (Figure 1.3 I).  
1.4.3 HCV RNA replication 
NS4B and NS5A induce the formation of ER-derived membrane spherules. In 
aggregate those are referred to as the membranous web where RNA replication is 
believed to take place (Egger et al. 2002; Romero-Brey et al. 2012). The NS5A 
phosphoprotein consists of three subunits. NS5A domains I and II are essential for 
RNA replication (Tellinghuisen et al. 2004; Tellinghuisen et al. 2008) while domain III 
assists in viral assembly (Appel et al. 2008; Tellinghuisen et al. 2008). NS5B is the 
RNA-dependent RNA polymerase. The NS3 protein is capable of nucleic-acid binding 
and 3‟ to 5‟ translocation coupled to hydrolysis of ATP (Raney et al. 2010). Although 
its exact role is unknown it might contribute to separation of nascent and template 
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RNA strands, unwinding RNA secondary structures or displacement of RNA-binding 
proteins (Figure 1.3 (d)).  
 
 
 
Figure 1.3: HCV life cycle. 
Schematic depiction of (a)Virus binding and internalization (b); cytoplasmic release and uncoating (c); IRES-
mediated translation and polyprotein processing (d); RNA replication (e); packaging and assembly (f); virion 
maturation and release . The topology of HCV structural and non-structural proteins at the endoplasmic reticulum 
membrane is shown schematically (Modified from(Moradpour et al. 2007)). 
 
1.4.4 Virus assembly and release 
Virus assembly and release is a tightly regulated process coupled to host cell lipid 
synthesis (reviewed in (Scheel et al. 2013)). After cleavage by host cell peptidases 
the mature core protein relocates from ER membranes to cytoplasmic lipid droplets 
(cLDs) (McLauchlan et al. 2002; Boulant et al. 2006). The current model for 
 nalyser din  formation involves interaction of core with NS5A, either on cLDs, 
whereto NS5A is directed by diacylglycerol acyltransferase-1 (DGAT-1), or after 
translocation from the mobile cLDs to the ER (Miyanari et al. 2007; Shavinskaya et 
al. 2007; Appel et al. 2008). Delivery of the HCV RNA genome is probably facilitated 
by the close proximity of sites of RNA replication and virion assembly and by NS2-
coordinated virion assembly through interactions with the glycoproteins, p7, NS3 and 
NS5A. A series of signal and stop-transfer sequences orchestrate ER translocation of 
the E1 and E2 glycoproteins, which assume a type I membrane protein topology. 
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After folding, heterodimer formation and addition of L-linked sugars, the E1-E2 
glycanes are then trimmed by glycosidases I and II (Lavie et al. 2007) 
(Figure 1.3 (e), (f)). 
1.5 HCV genotypes and distribution 
Due to the missing proof-reading function of the HCV RNA-dependent RNA 
polymerase there is a high error rate in genome replication resulting in approximately 
104 to 105 nucleotide exchanges per generation (Holland et al. 1982; Drake et al. 
1998). Frequent point mutations result in a swarm of heterogeneous but closely 
related virus variants in the same host termed quasispecies. The balance between 
mutation and selection within certain populations is believed to result in different viral 
genotypes (Domingo et al. 2006). Based on genetic divergence HCV can be 
subdivided into 7 genotypes (1-7) with approximately 30% sequence divergence and  
multiple subtypes (a,b,c…) with up to 20% sequence divergence (Gottwein et al. 
2008). Distinct genotypes predominate in different parts of the world. Genotype 1 
dominates in North America (70%), Japan (75%) and Europe (50 to 70%), genotypes 
2 and 3 are also frequent in these regions. Genotypes 3 and 6 are widespread in 
South Asia and South East Asia and genotype 4 and 5 are most common in Africa, 
but have recently also spread to Europe. Genotype 7 was recently found in a few 
patients from Central Africa.  
 
Disease progression is largely similar across genotypes. For reasons yet unknown 
different genotypes show different response rates to treatment with IFN-based 
therapies. A sustained viral response (SVR) after treatment is obtained in nearly 80% 
of genotype 2 and 3 infected individuals and only 50% of genotype 1 infected 
individuals (Manns et al. 2006). Inhibitors of the non-structural proteins NS3-NS4A 
protease proofed to be a powerful antiviral drug for HCV treatment. However, owing 
to genotype-dependent efficacy, NS3-NS4 protease inhibitors Telaprevir and 
Boceprevir are approved for treatment of genotype 1 only. The results achieved with 
this treatment led to SVR rates as high as 75% (Jensen 2011). 
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1.6 HCV epidemiology 
HCV was assigned to the family of NonA-/NonB hepatitis viruses for a long time 
before Michael Houghton and his group managed to isolate viral RNA from an 
infected chimpanzee and created cDNA clones in 1989 (Choo et al. 1989). In fact 
80% to 90% of NonA-/NonB hepatitis could be attributed to HCV (Alter et al. 1989).  
 
It has been suggested that the initial spread of the virus started during the last 
century through the use of unsafe parenteral injections, invasive medical and surgical 
procedures and transfusion of blood products and was subsequently spread by 
intravenous drug use among younger people.  HCV prevalence in European counties 
is heterogeneous ranging from less than 0.5% prevalence in Scandinavian countries 
to up to 7% to 20%  in Italy and Greece (Figure 1.4) (Dellabona et al. 1994; Stroffolini 
et al. 1995; Guadagnino et al. 1997; Lionis et al. 1997; Osella et al. 1997; Goritsas et 
al. 2000; Maio et al. 2000; Raffaele et al. 2001), The high HCV prevalence in these 
areas is owed to the widespread use of unsafe medical procedures in the distant past 
(Wasley et al. 2000; Shepard et al. 2005; Prati 2006). In the late 1980s, 2% to 10% of 
blood units in developed countries were HCV infected, thus successfully spreading 
the infection (Alter et al. 1981; Colombo et al. 1987; Esteban et al. 1990; Prati 2006). 
Nowadays the risk to receive an HCV positive blood transfusion is 1:100000 and no 
case of HCV transmission due to the administration of plasma-derived products has 
been reported since 1994 (Prati 2006) leaving intravenous drug use as the major 
cause of HCV transmission.  
1.6.1 Injection drug use and the HCV epidemic  
As reviewed by Esteban et al. (Esteban et al. 2008) intravenous drug use has 
become the main transmission mechanism for HCV in Western Europe (Shepard et 
al. 2005), accounting for 60% to 90% of prevailing infections in certain European 
countries (Harris et al. 1999; Westin et al. 1999; Dalgard et al. 2003; Hutchinson et 
al. 2006; Sutton et al. 2006). Estimates by the European Monitoring center for Drugs 
and Drug Addiction (EMCDDA) and Eurosurvaillance suggest a rate of 5.3 
intravenous drug users (IDUs) per 1000 population aged 16 to 64, resulting in at least 
1.7 million IDUs in European countries alone.  
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Figure 1.4: Estimated HCV prevalence in different European countries. 
(Esteban et al. 2008) 
1.6.2 Injection drug use and the HCV epidemic       
As reviewed by Esteban et al. (Esteban et al. 2008) intravenous drug use has 
become the main transmission mechanism for HCV in Western Europe (Shepard et 
al. 2005), accounting for 60% to 90% of prevailing infections in certain European 
countries (Harris et al. 1999; Westin et al. 1999; Dalgard et al. 2003; Hutchinson et 
al. 2006; Sutton et al. 2006). Estimates by the European Monitoring center for Drugs 
and Drug Addiction (EMCDDA) and Eurosurvaillance suggest a rate of 5.3 
intravenous drug users (IDUs) per 1000 population aged 16 to 64, resulting in at least 
1.7 million IDUs in European countries alone.  
 
HCV transmission is reported to occur rapidly after initiation of intravenous drug use 
especially within the first year (Sutton et al. 2006). After 5 years 50% to 90% of users 
have been exposed to HCV (Villano et al. 1997). Additional factors associated with 
an increased risk of HCV infection include age, duration and frequency of IDU, 
sharing equipment, polydrug use, HCV prevalence among experienced IDUs, 
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homelessness and having served a prison sentence (Villano et al. 1997; Garfein et 
al. 1998; Hagan et al. 2001; Judd et al. 2005; Mathei et al. 2006; Hickman et al. 
2007). Most new HCV infections occur in young IDUs and the proportion of patients 
with IDU-related chronic HCV has surpassed those infected by other routes 
(Haushofer et al. 2001; Bourliere et al. 2002; Schroter et al. 2002; Gerard et al. 2005; 
Payan et al. 2005; Katsoulidou et al. 2006). In addition, IDU-related genotypes (1a, 
3a and 4) have replaced the classical transfusion associated genotypes 1b and 2 
among blood donors and young patients (Haushofer et al. 2001; Bourliere et al. 
2002; Schroter et al. 2002; Gerard et al. 2005; Payan et al. 2005; Katsoulidou et al. 
2006). IDUs are repetitively exposed to different HCV genotypes and while one could 
speculate that patients who have cleared infection, either spontaneously or upon 
treatment,  carry protective immunity against reinfection, this does not seem to be the 
case (Dalgard et al. 2002; Backmund et al. 2004; Micallef et al. 2007; Currie et al. 
2008; Bate et al. 2010; Grebely et al. 2010; Grady et al. 2012), suggesting a lack of 
sterilizing immunity. However the incidence of reinfection is low compared to 
acquisition of primary HCV infections (Mehta et al. 2002; Backmund et al. 2004; 
Grebely et al. 2006; Grady et al. 2012), indicating that resolved HCV infection is at 
least associated with partial protection. In a recent epidemiological study of IDUs 
living in Germany 45.2% of IDUs were HCV-RNA positive, another 27.9% were anti-
HCV positive but HCV-RNA negative consistent with resolved HCV infection 
(Zimmermann 2012). Interestingly an additional 26.9% of IDUs were anti-HCV 
negative although the reported risk behavior suggests that they have been exposed 
to the HCV. It has been highlighted in numerous studies that both the innate and the 
adaptive immune response are important for spontaneous immune control of HCV 
(reviewed in (Rehermann 2009)) but it is largely unclear if the immune response 
contributes to protection against productive HCV infection in those IDUs who remain 
seronegative. 
1.7 Humoral immune responses 
The importance of antibodies in HCV infection has long been underestimated as it  
was demonstrated that antibody-deficient patients are able to clear HCV infection 
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(Semmo et al. 2006). Only recently the discussion about neutralizing antibodies in 
HCV infection (reviewed by (Fafi-Kremer et al. 2012)) has been revitalized. 
 
The antibody response to HCV in vivo is directed against several viral proteins (Chen 
et al. 1999), however neutralizing Antibodies (Abs) that block HCV entry are 
specifically directed towards the viral envelope, particularly envelope glycoprotein E2. 
Functional analysis and neutralization experiments using sera from chronically HCV 
infected patients have demonstrated that host neutralizing responses target viral 
entry at a step after initial HCV binding, most likely by interrupting HCV E2-CD81 or 
HCV E2-SR-BI interactions, or by inhibiting membrane fusion (Haberstroh et al. 
2008). Although hyper variable region I (HVRI), a region in the E2 protein displaying 
high genetic variability that is involved in viral entry (Bartosch et al. 2003), assembly, 
release of virus particles and membrane fusion (Bankwitz et al. 2010), is a primary 
target of neutralizing antibodies, these antibodies exhibit poor cross-neutralizing 
potency (Wang et al. 2011). Antibodies that demonstrate broadly neutralizing activity 
tend to be directed against conserved epitopes within E2 and most often inhibit the 
interaction between CD81 and E2 (Owsianka et al. 2001; Clayton et al. 2002; Triyatni 
et al. 2002; Hsu et al. 2003; Keck et al. 2008). While anti-HCV antibodies are 
generally detected in HCV infection, a strong and early production of neutralizing Abs 
during acute infection may contribute to control of the virus and facilitate viral 
elimination by cellular immune responses (Lavillette et al. 2005; Pestka et al. 2007; 
Dowd et al. 2009). In addition neutralizing Abs have been found in patients that 
spontaneously cleared HCV reinfection, indicating that cross-neutralizing humoral 
responses are able to decrease or even control viremia (Osburn et al. 2010). Despite 
the existence of neutralizing Abs in vivo the majority of patients develop chronic HCV 
infection, this is owed to genetically distinct, but closely related HCV variants within 
the quasispecies, allowing the rapid selection of mutants which are best adapted to 
the host environmental changes, hence the virus could persist in the presence of 
neutralizing Abs (von Hahn et al. 2007).    
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1.8  T cell responses 
While the role of antibodies has long been controversial, HCV-specific T cells are 
critical in HCV clearance (reviewed in (Rehermann 2013). Strong CD4 helper and 
CD8 effector T cell responses have been observed in patients that clear HCV 
infection (Lechner et al. 2000). Vigorous proliferation and activation of CD4 T cells is 
observed in patients that later go on to resolve HCV infection (Figure 1.5A), while 
CD4 T cell responses are rare or absent in those who later develop chronic HCV 
infection (Figure 1.5B) (Missale et al. 1996). In contrast to CD4 T cells, CD8 T cells 
appear to be stunted in acute HCV infection (Kaplan et al. 2007), displaying 
decreased proliferation, IFN-γ production and cytotoxicity (Lechner et al. 2000; 
Thimme et al. 2001; Urbani et al. 2002) as well as increased levels of programmed 
death 1(PD-1) (Kasprowicz et al. 2008). However, dysfunction of CD8 T cells 
resolves and protective CD8 T cells expressing the IL-7 receptor α-chain, CD127, 
develop with the onset of CD4 activation and the decline of viral titers (Lechner et al. 
2000; Thimme et al. 2001; Urbani et al. 2002). 
 
While T cells are able to clear acute HCV infection, chronic HCV infection is 
associated with continuous activation yet impaired function and reduced breadth of 
HCV-specific T cells (Wedemeyer et al. 2002; Cox et al. 2005). Prolonged exposure 
to viral antigens is the main cause for the reduced frequency and impaired effector 
function of virus-specific CD8 T cells, summarized as T cell exhaustion (Bucks et al. 
2009; Mueller et al. 2009). T cell exhaustion follows a predictable model, first T cells 
lose their ability to produce IL-2, followed by sequential loss of cytotoxicity and TNF-α 
and IFN-γ production. In addition, the intracellular expression of proapoptotic proteins 
such as Bsl2-interasting mediator (Bim) increases in virus-specific CD8 T cells 
(Larrubia et al. 2013). Accordingly T cells of chronically HCV infected individuals 
display increased expression of PD-1 (Penna et al. 2007; Radziewicz et al. 2007; 
Nakamoto et al. 2009; Bengsch et al. 2010), cytotoxic T lymphocyte antigen 4 (CTLA-
4) (Radziewicz et al. 2007; Nakamoto et al. 2009), T cell immunoglobulin and mucin 
domain-containing molecule 3 (Tim-3) (Golden-Mason et al. 2009; McMahan et al. 
2010) and 2B4 (Nakamoto et al. 2009; Schlaphoff et al. 2011). Additionally the 
corresponding ligands are upregulated in the inflamed liver. In addition, an 
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inflammation-induced increase in regulatory T cell counts (Sugimoto et al. 2003) and 
a shift from T cell activating cytokines like interleukin-2 (IL-2) (Radziewicz et al. 2007) 
towards inhibiting cytokines like IL-10 and transforming growth factor-β (TGF-β) 
(Accapezzato et al. 2004; Alatrakchi et al. 2007) dampens virus specific T cell 
responses.  
 
Figure 1.5: Schematic representation of the cellular immune response during acute HCV infection. 
(4) Early onset and maintained CD4 and CD8 T cell responses mediate viral clearance and lead to 
resolution of HCV infection. (B) Week CD4 and CD8 T cell responses are unable to clear HCV infection 
and decrease over time allowing persistent HCV infection (Modified from (Bowen et al. 2005)). 
 
Finally HCV recognition by T cells is further hindered by escape mutations in T cell 
epitopes (Aldrich et al. 1994; Chang et al. 1997; Timm et al. 2007; Neumann-Haefelin 
et al. 2011). While protective T cell responses tend to be directed against epitopes 
that do not allow escape mutations because of high costs to viral replicative fitness, 
viral mutations in dominant T cell epitopes are selected to establish chronic infection, 
A
B
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rendering existing T cell responses irrelevant. Interestingly, while novel T cell 
responses against HCV epitopes at later stages of infection are rare, (Cox et al. 
2005) induction of T cell responses to unrelated antigens is not impaired.  
1.9 HCV and innate immunity 
HCV is sensed as non-self by pattern recognition receptors (PRRs) leading to 
activation of the innate immune system and subsequently adaptive immunity. The 
main receptors responsible for HCV recognition are retinoic acid inducible gene-I 
(RIG-I), Toll-like receptor 3 (TLR3) and protein kinase R (PKR) (reviewed by (Horner 
et al. 2013).  
 
RIG-I is a cytosolic PRR sensing RNA viruses. It binds to RNA that includes an 
exposed 5‟ triphosphate and the 3‟ untranslated region, which is rich in poly U/UC 
ribonucleotides (Saito et al. 2008; Uzri et al. 2009). HCV RNA binding induces a 
conformational change that promotes its oligomerization and translocation from the 
cytosol into intracellular membranes (Saito et al. 2007; Jiang et al. 2011; Liu et al. 
2012). Together with the chaperone protein 14-3-3ε and the ubiquitin ligase TRIM25, 
RIG-I makes up a translocon that facilitates the interaction of RIG-I with mitochondrial 
antiviral signaling proteins (MAVS) (Gack et al. 2007; Liu et al. 2012). The RIG-I 
MAVS interaction promotes the formation of a MAVS signalosome that propagates 
activation of downstream effector molecules, including the transcription factors 
interferon regulatory factor-3 (IRF-3), nuclear factor-κB (NF-κB) and a variety of 
proinflammatory cytokines (Loo et al. 2011) (Figure 1.6). 
 
TLR3 is an endosomal sensor of dsRNA expressed in a number of cell types within 
the liver, including hepatocytes and the liver-resident macrophages called Kupffer 
cells (Seki et al. 2008; Wang et al. 2009). TLR3 signals are transmitted through the 
adaptor protein TIR-domain-containing adaptor-inducing interferon-β (TRIF), which 
activates IRF-3 and NF-κB for the production of type I interferons (IFNs), 
proinflammatory cytokines and chemokines, as well as apoptotic signaling (Salaun et 
al. 2006; Takeuchi et al. 2009). However, in contrast to synthetic TLR3 ligands that 
trigger TLR3 mediated activation within 24 h after stimulation, activation via HCV 
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RNA takes up to three to four days (Wang et al. 2009; Li et al. 2012). In addition, 
cytokine induction profiles after TLR3 activation using the TLR3 agonist polyinosine-
cytosine (poly I:C) and HCV RNA differ, suggesting HCV-TLR3 interaction has some 
level of specificity (Wang et al. 2009; Li et al. 2012). During HCV infection TLR3-
mediated signaling could serve as a secondary innate immune detection or 
surveillance system for uninfected cells after RIG-I detection of HCV, and it could be 
involved in setting up an antiviral state within regions of the liver or in chemokine 
induced T cell recruitment (Wang et al. 2009) (Figure 1.6).  
 
PKR is a dsRNA–binding protein whose kinase activity can be induced by binding to 
HCV dsRNA to phosphorylate the α subunit of eukaryotic initiation factor 2 (eIF2α). 
However, this only downregulates host mRNA translation, as HCV is independent of 
eIF2α due to the lack of a 5‟ cap structure (Koev et al. 2002; Garaigorta et al. 2009; 
Shimoike et al. 2009; Arnaud et al. 2010). It is known that PKR binding of HCV 
dsRNA also activates a kinase-independent signal transduction cascade that drives 
induction of specific IFN-stimulated genes (ISGs) and IFN-β production by signaling 
through MAVS, tumor necrosis factor (TNF) receptor-associated factor 3, IRF and 
NF-κB, all before RIG-I activation (Kumar et al. 1997; McAllister et al. 2009; Arnaud 
et al. 2010) (Figure 1.6). 
1.9.1 HCV evasion of innate antiviral immunity 
The NS3-NS4A protease is a central component of the HCV innate immune evasion 
strategy. It is anchored to intracellular membranes through the NS4A transmembrane 
domain and an amphipathic α-helix at the NS3 N-terminus that facilitates membrane 
association and cleavage of membrane anchored substrates (Brass et al. 2008; 
Horner et al. 2012). Hence NS3-NS4A targets and cleaves MAVS from intracellular 
membranes and prevents signal transduction (Foy et al. 2003; Foy et al. 2005; 
Meylan et al. 2005; Baril et al. 2009; Loo et al. 2011) (Figure 1.6 (1,3)). This cleavage 
event prevents activation of the RIG-I pathway and downstream signaling events 
including IFN induction. In addition, the NS3-NS4A protease also proteolytically 
targets TRIF (Li et al. 2005)(Figure 1.6 (4)), the TLR3 signaling adaptor proteins, thus 
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preventing TLR3 signaling as well. In combination theses cleavage events abrogate 
IFN induction and support progression to chronic infection.  
 
 
 
Figure 1.6: HCV recognition by and evasion from innate immunity.  
HCV is sensed by the PRRs RIG-I (3), TLR3 (4) and PKR (1,2) and evades innate immunity by cleavage of host 
factors. The proposed regulation is depicted above. The HCV NS3-NS4A protease cleaves the signaling adaptors 
MAVS (indicated by the dashed box) and TRIF to inactivate PKR (1), RIG-I (3) and TLR3 (4) signaling pathways 
to prevent induction of immunomodulatory innate antiviral genes and IFN-, allowing for HCV replication. HCV 
infection control of IFN-induction is not yet defined (5); HCV E2 and NS5A proteins inactivate PKR-dependent 
activation of the host translation factor eIF2to reactivate protein translation during infection (2)(Horner et al. 
2013). 
1.10 Influence of host genetics on HCV infection outcome 
Several factors influence spontaneous clearance of HCV infection as well as 
treatment outcome including HLA-type, ethnicity, gender, age and obesity. 
Furthermore, high baseline levels of ISGs predict an unfavorable outcome of HCV 
therapy (Kau et al. 2008). Single nucleotide polymorphisms (SNPs) upstream of the 
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IFNL3 (also referred to as IL28B) locus that can predict both successful clinical 
outcome to HCV therapy (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009; 
Rauch et al. 2010) and spontaneous resolution have been identified (Thomas et al. 
2009; Rauch et al. 2010). Theses SNPs associate with altered mRNA expression of 
IFNL3, which encodes the anti viral cytokine IFNL3, which suggests that IFNL3 
expression levels are probably associated with HCV clearance and response to 
therapy (Suppiah et al. 2009; Tanaka et al. 2009; Dill et al. 2011). In fact, is has been 
shown that the unfavorable SNP results in less IFNL3 expression in the liver, 
peripheral blood mononuclear cells and whole blood (Suppiah et al. 2009; Tanaka et 
al. 2009; Fukuhara et al. 2010; Dill et al. 2011; Langhans et al. 2011). A recent study 
showed that patients with the unfavorable IFNL3 genotype have depressed innate 
immune function, particularly with respect to NK cells (Naggie et al. 2012), 
suggesting the decreased expression of IFNL3 affects immunity and therefore 
clearance of HCV. Similar to the IFNL3 genotype, the KIR2DL3 and HLA-C1 
genotype have been associated with spontaneous resolution of HCV infection 
(Khakoo et al. 2004) as well as resistance to HCV infection (Knapp et al. 2010). 
Although it is well known that the KIR2DL3 gene encodes for the inhibiting natural 
killer (NK) cell receptor KIR2DL3 and that HLA-C1 molecules are the respective 
ligands for this receptor, the mechanisms underlying this protective effect remain 
elusive. However, different NK cell phenotypes have repeatedly been associated with 
HCV infection outcome.  
1.11 Natural killer cells  
1.11.1 Natural killer cells in viral infections 
NK cells constitute a population of bone marrow derived, low-density, large granular 
lymphocytes that make up 10–15% of the Peripheral Blood Mononuclear Cell 
(PBMC) and are strongly enriched in the liver (Doherty et al. 2000). They lack the 
normal B and T cell lineage markers (CD19 and CD3) and are usually characterized 
by the expression of CD56, the neural cell adhesion molecule, and CD16, the Fcγ 
receptor III, which mediates antibody dependent cellular cytotoxicity (ADCC).  
They are able to spontaneously kill virally infected and tumor cells without prior 
sensitization by surveillance of danger signals including down regulation of major 
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histocompatibility complex (MHC) class I molecules (“missing self”) (Ljunggren et al. 
1990) and upregulation of MHC class I homologues (“induced self”) (Raulet 2003) as 
well as direct recognition of pathogen associated molecules (Yokoyama et al. 2004; 
Lanier 2005). NK cells are able to mediate viral control in various ways. They can 
directly kill infected cells by release of granzyme and perforin from cytotoxic granules 
(Farag et al. 2006) or limit viral replication by production of cytokines like IFN-γ 
(Moretta et al. 2002). In addition, they are able to recruit other lymphocytes to the site 
of infection, including T cells (Zingoni et al. 2005; Welsh et al. 2013) and dendritic 
cells (DC) (Fernandez et al. 2002).  
1.11.2 NK cell receptors  
NK cell activation is controlled by a complex set of activating and inhibiting receptors 
on the NK cell surface. The receptor repertoire varies between patients and is known 
to influence HCV infection outcome. In humans the majority of NK cell receptors can 
be grouped into three receptor families. 
1.11.2.1 The killer cell immunoglobulin-like receptor (KIR) family  
KIRs are type I integral membrane glycoproteins that are usually expressed as 
monomers on the cell surface (Lanier 1998; Long 1999). KIR receptors are 
subclassified based on the number of Ig domains of the extracellular part (KIR2D/3D) 
and the length of the cytoplasmic tail. The ones with long cytoplasmic tails 
(KIR2D/3DL) have two immunoreceptor tyrosine-based inhibition motifs (ITIMs) and 
are inhibiting receptors. Those with a short cytoplasmic tails (KIR2D/3DS) associate 
with a dimer of the immunoreceptor tyrosine-based activation motif (ITAM) bearing 
adapter protein DAP12 and mediate activating signals (Lanier et al. 1998) 
(Figure1.7A). The receptors are further numbered differently if they show more than 
2% sequence divergence within the group. The ligands for KIR receptors are HLA 
molecules.  
1.11.2.2 NKG2/CD94 receptors 
NKG2/CD94 receptors are type II C-type, lectin-like, integral membrane glycoproteins 
that are expressed on the cell surface as a heterodimer with CD94 (Figure 1.7B). 
CD94 has no signaling properties and only serves to stabilize NKG2 on the cell 
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surface. Four distinct genes A/B, C, D, E/H, and F encode the NKG2 receptors 
(Lanier 1998; Long 1999; Diefenbach et al. 2001). Only the NKG2A/CD94 receptor 
has a long cytoplasmic tail containing two ITIMs, thus mediating inhibiting signals to 
the NK cell. The other members of the NKG2 family mediate activating signals and 
associate with DAP12 (Lanier et al. 1998). NKG2 receptors bind HLA-E (Borrego et 
al. 1998; Braud et al. 1998; Lee et al. 1998), whose expression requires peptides 
derived from signal sequences of HLA-A, -B, -C, and –G (Leibson 1998).  
 
NKG2D represents an exception within the NKG2 family. Unlike the other family 
members it forms a homodimer on the cell surface (Figure 1.7B). Its ligands are the 
stress induced non-classical MHC class I molecules MIC-A/B and ULBP1-4. Upon 
binding NKG2D mediates activating signals to the NK cell (Bauer et al. 1999; Wu et 
al. 1999).  
 
 
 
Figure 1.7: The KIR and NKG2/CD94 receptor families. 
(4) KIR receptors are named KIR2D (left) or KIR3D (right) according to the number of IG domains 
expressed. Inhibiting KIR receptors have a long cytoplasmic tail with two ITIM motive (green). Activating 
KIRs have a short cytoplasmic tail and associate with ITAM (red) containing adapter proteins. (B) 
Members of the NKG2 receptor family usually associate with a CD94 molecule. NKG2D represents an 
exception forming hetero dimmers. Activating members of the NKG2 family associate with ITAM bearing 
adapter proteins. The inhibiting NKG2A receptor has a cytoplasmic tail containing ITIMs.    
 
1.11.2.3 Natural cytotoxicity receptors (NCR) 
NKp30, NKp44, and NKp46 are NCR (Figure 1.8). They belong to the Ig superfamily 
and trigger NK cell activation upon engagement. NKp46 and NKp30 are expressed 
on resting and activated NK cells, whereas NKp44 is expressed on activated NK cells 
KIR2DL KIR2DS KIR3DL KIR3DS CD94/ NKG2A CD94/ NKG2C NKG2D
ITIM
ITAM
adapter 
protein
A B
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(Biassoni et al. 2001; Moretta et al. 2001). NKp46 binds the sialic acid-binding 
glycoproteins, e.g., hemagglutinin and hemagglutinin-neuraminidase of the influenza 
and parainfluenza viruses, respectively (Mandelboim et al. 2001). NKp44 bind to the 
E2 protein of West Nile and Dengue virus (Hershkovitz et al. 2009). Other ligands for 
NCRs are not conclusively defined.  
 
 
Figure 1.8: Schematic drawing of  NKp46, NKp30 and NKp44. 
NKp46, NKp30 and NKp44 are activating NK cell receptors associated with ITAM bearing adapter proteins.   
 
1.11.3 NK cell differentiation 
Based on the expression of CD56 and CD16 NK cells are subdivided into three 
distinct subsets. About 10% of NK cells in the peripheral blood are CD56bright CD16-. 
This immunoregulatory subset produces a wide range of cytokines and chemokines 
after stimulation, but its ability to spontaneously kill target cells is poor. In contrast, 
the remaining 90% of NK cells, the CD56dimCD16+ cytotoxic NK cell subset, produce 
lower cytokine levels, but possess an abundance of cytolytic granules and can 
spontaneously lyse susceptible target cells (Poli et al. 2009). The third subset, CD56-
CD16+ NK cells, are rare but were described to be expanded in HIV infection (Hu et 
al. 1995). These NK cells display impaired functionality and are believed to be 
anergic NK cells (Hu et al. 1995; Alter et al. 2005).  
NK cells differentiate from CD56bright to CD56dim to CD56- NK cells (Ouyang et al. 
2007; Romagnani et al. 2007). While almost all CD56bright NK cells express NKG2A 
on their cell surface, differentiation of NK cells from CD56bright to CD56dim is 
accompanied by the sequential loss of NKG2A and acquisition of KIRs, CD57 and 
ITAM
adapter 
protein
Ig domain
NKp46 NKp30 NKp44
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NKG2C (Beziat et al. 2010; Bjorkstrom et al. 2010; Beziat et al. 2012). It is well 
established that KIRs, in conjunction with NKG2A, play a major role in NK cell 
education that determines whether NK cells will end up competent or 
hyporesponsive. The mechanisms underlying this education are still debated. 
However, the most likely model to date is a hypothesis proposing that the 
engagement of self-MHC-specific inhibitory receptors (KIRs) directly renders NK cells 
functional, “licensing” them so to speak.  
1.12 NK cells in HCV infection 
1.12.1 NK cells in acute HCV infection  
The phenotype of NK cells has repeatedly been associated with HCV infection 
outcomes. Increased IFN-γ production, cytotoxicity and degranulation have been 
described in acute HCV infection (Amadei et al. 2010; Pelletier et al. 2010), however 
NK cell activation did not correlate with subsequent infection outcome. Phenotypical 
changes have also been observed in acute HCV infection. Amadei et al. report 
increased frequencies of NKG2D expressing NK cells, yet this phenotype is not 
associated with a specific infection outcome (Amadei et al. 2010). Alter et al. on the 
other hand report lower frequencies of NKp46+ and NKp30+ NK cells in acutely 
infected patients that go on to clear infection (Alter et al. 2011). These findings are 
somewhat counterintuitive as recent reports associate high levels of NKp30 (Golden-
Mason et al. 2010) and NKp46 (Sivori et al. 1999; Kramer et al. 2012) with HCV 
clearance. Alter et al. suggest that this downregulation might be explained by earlier 
vigorous NK cell activation and subsequent downregulation of activating NK cell 
receptors (Alter et al. 2011).  
1.12.2 NK cells in chronic HCV infection  
While data about NK cells in acute HCV infection is scarce, numerous studies on NK 
cells in chronic HCV infection exist. Several studies report reduced NK cell 
frequencies in the peripheral blood of chronically HCV infected patients compared to 
healthy controls (Meier et al. 2005; Morishima et al. 2006; Bonorino et al. 2009; 
Oliviero et al. 2009) as well as decreased intrahepatic NK cell levels (Kawarabayashi 
et al. 2000; Deignan et al. 2002; Bonorino et al. 2009). Altered subset distribution 
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characterized by decreased frequencies of CD56dim and/or increased frequencies 
CD56bright NK cells is a consistent finding (Golden-Mason et al. 2008; Bonorino et al. 
2009). Several NK cell receptors have been reported to be differentially expressed in 
HCV infection (reviewed in (Cheent et al. 2011)). However, conflicting data on the NK 
cell phenotype in chronic HCV infection exists. This variance may arise from 
differences in methodology, control groups used, the use of fresh or frozen blood 
samples and small sample sizes. However, one of the most consistent findings links 
an expansion of NKG2A+ NK cells to chronic infection (Jinushi et al. 2004; 
Nattermann et al. 2005; Nattermann et al. 2006; Ahlenstiel et al. 2010), which 
suggests inhibition of NK cell function. Several lines of evidence suggest skewing or 
polarization of NK cell function away from IFN-γ production towards cytotoxicity 
(Oliviero et al. 2009; Ahlenstiel et al. 2010; Dessouki et al. 2010; Mondelli et al. 
2012). Insufficient IFN-γ responses may result in increased viral replication, as IFN-γ 
has direct antiviral properties and can control viral replication (Boehm et al. 1997; 
Rotondi et al. 2011) while enhanced cytotoxicity may promote liver damage 
(Ahlenstiel et al. 2010).  
 
Lately, new data from the lymphocytic choriomeningitis virus (LCMV) mouse model 
suggested that NK cells kill activated T cells in chronic viral infection. Lang et al. 
demonstrated that NK cells have a negative impact on the development of T cell 
immunity during LCMV infection. NK cell deficient mice exhibited a higher virus-
specific T cell response. In addition, NK cell depletion in wild type mice caused 
increased T cell immunity and viral clearance (Lang et al. 2012). A similar study in 
the LCMV model by Waggoner et al. describes a three-way interaction, whereby 
activated NK cells cytolytically eliminate activated CD4 T cells, which affects CD8 T 
cell function and exhaustion. At high virus doses, NK cells prevented fatal pathology 
while enabling T cell exhaustion and viral persistence, but at medium doses NK cells 
facilitated lethal T cell-mediated pathology, thus suggesting that NK cells act as 
regulators of T cell immunity (Waggoner et al. 2012). Importantly, similar findings 
were made in human HBV infection. Peppa et al. found that NK cells can rapidly 
eliminate HBV-specific T cells in a contact-dependent manner. CD8 T cells in the 
liver microcirculation were visualized making intimate contact with NK cells. These 
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findings demonstrate that NK cells can negatively regulate antiviral immunity in 
chronic HBV infection illustrating a potential novel mechanism of T cell tolerance in 
the human liver (Peppa et al. 2013). Taken together this data suggests that NK cell 
activation might be detrimental in chronic viral infection and supports ongoing 
chronicity, while inactive NK cells allow vigorous T cell responses and viral clearance. 
1.12.3 NK cells in HCV exposed seronegative individuals 
Khakoo et al. have described a strong genetic association between homozygosity for 
the NK cell receptor gene KIR2DL3 and its ligand HLA-C1 group alleles and 
spontaneous clearance of HCV infection in IDUs (Khakoo et al. 2004). Interestingly, 
the same genetic association was confirmed in HCV seronegative IDUs (Knapp et al. 
2010; Knapp et al. 2011), while a phenotypic analysis of NK cells described 
increased levels of NKp30 in HCV seronegative IDUs (Golden-Mason et al. 2010). 
Importantly, a recent study demonstrated activation of the NK cell compartment after 
needle stick exposure to HCV without subsequent seroconversion (Werner et al. 
2013), confirming that NK cells act against HCV prior to induction of adaptive immune 
responses. Taken together with reports that IL-6 and IL-8, modulators of innate 
immunity, are upregulated in serum of HCV exposed seronegative individuals 
(Warshow et al. 2012), this data indicates an important role of NK cells in early 
immune control of HCV infection.  
1.13 Aim of the study  
In a recent epidemiological study of IDUs living in Germany 45.2% of IDUs were 
HCV-RNA positive, another 27.9% were anti-HCV positive but HCV-RNA negative 
consistent with resolved HCV infection and the remaining 26.9% of IDUs were anti-
HCV negative (Zimmermann 2012). The frequently reported shared use of drug 
injection equipment suggests that most IDUs in cohorts with high HCV prevalence 
rates are exposed to HCV (Scherbaum et al. 2009; Pouget et al. 2012). Indeed, the 
existence of HCV-specific CD8 T cell responses in a subset of seronegative IDUs 
supports prior exposure to HCV (Thurairajah et al. 2008; Cameron et al. 2013). 
Studies by Khakoo et al. and Knapp et al. suggest that KIR2DL3 is the main player in 
refering resistence to HCV infection (Khakoo et al. 2004; Knapp et al. 2010). These 
studies show a strong corellation between homozygosity for KIR2DL3 and HLA-C1 
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and spontaneous clearance of HCV as well as resistence to HCV infection. As 
KIR2DL3 is not exclusively expressed on NK cells (Paust et al. 2010) and those 
studies refered to the genotype alone and phenotypical analysis are not included, the 
aim of this sudy is to analyze NK cells of seronegative IDUs in more detail to answer 
the following questions: 
 
 Is there an NK cell phenotype that can mediate “a state of natural resistence” 
to HCV infection? 
 
 What is the role of KIR2DL3 in mediating resistance to HCV? 
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2 Materials 
2.1 Chemicals and reagents 
BDTM Comp beads, anti mouse Ig κ Becton Dickinson 
Biocoll Separating Solution Biochrome  
Bright-Glo™ Luciferase Assay System Promega 
Dimethylsulfoxid (DMSO) Roth 
Dulbecco‟s Phosphate-Buffered Saline, 1X (DPBS) Gibco 
Ethanol Sigma-Aldrich  
FACS-Clean Becton Dickinson 
FACS-Flow Becton Dickinson 
FACS-Rinse Becton Dickinson 
Glo Lysis buffer  Promega 
IC Fixation Buffer  eBioscience 
Isopropanol Sigma-Aldrich 
Permeabilization Buffer (10X) eBioscience 
2.2 Cell culture media and additives 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 1M PAA 
Brefeldin A (BFA) Sigma Aldrich 
Dulbecco‟s Modified Eagle‟s Medium (DMEM) PAA 
Fetal bovine serum (FBS) Biochrome  
G-418 Biochrome  
Interferon (IFN)- α  Promokine  
Non-essential amino acids PAA 
p815-specific antibody Abcam 
Penicillin/Streptomycin (100X) PAA 
RPMI 1640 + L-Glutamin  PAA 
Trypsin/ EDTA (100X) PAA 
α-Galactosylceramide (α-GalCer) Funakoshi 
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2.3 Eukaryotic cell lines 
2.3.1 Human acute myelocytic leukemia cell line K562 (K562) 
K562 cells are human immortalized myelogenous leukemia cells obtained from a 53 
year old female patient with chronic myelogenous leukemia undergoing blast crisis 
(Lozzio et al. 1975). Due to a lack of MHC molecules on their surface they are easily 
killed by NK cells (Lozzio et al. 1979). 
2.3.2 K562 HLA-E 
K562 HLA-E cells are K562 cells stably transfected with HLA-E*01033 (Nattermann 
et al. 2005). 
2.3.3 LCL721.221 cells (221) 
LCL721.221 cells are a subline of the human B lymphoblastoid cell line (LCL) 721 
with γ-ray induced HLA antigen loss (Shimizu et al. 1989).  
2.3.4 Primary human hepatocytes  
Primary human hepatocytes were isolated from liver tissue of patients undergoing 
liver transplantation and obtained from the department of gastroenterology. 
2.3.5 Murine lymphoblast-like mastocytoma cell line p815 (p815) 
Murine lymphoblast-like mastocytoma cell line p815 cells are used to assess 
antibody-dependent cell-mediated cytotoxicity of NK cells. For that purpose p815 
cells were coated with p815 specific antibody and subsequently used as target cells 
for NK cells.    
2.4 Cell culture media composition  
K562, LCL 721.221, p815,    RPMI 1640 
PBMC (R10)      10% FBS 
       100 U/mL penicillin  
100 µg/mL streptomycin 
       10 mM HEPES 
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K562 HLA-E      RPMI 1640  
       10% FBS 
       100 U/mL penicillin  
100 µg/mL streptomycin 
       10 mM HEPES 
       300 U/mL G-418 
 
Freezing medium      FBS 
       10% DMSO 
 
Primary human hepatocytes (PHH)  DMEM/ Ham´s F12 
10% FBS 
       100 U/mL penicillin  
100 µg/mL streptomycin 
2.5 Commercial Kits 
3„ IVT Express Kit Affymetrix 
ArCTM Bead Kit  Invitrogen 
EasySep™ Human NK Cell Enrichment Kit Stemcell Technologies 
EasySep™ Human PE Positive Selection Kit Stemcell Technologies 
Experion RNA StdSens Analysis Kit Bio-Rad 
LiaisonTM CMV IgG II DiaSorin  
LightCycler FastStart DNA MasterPLUS HybProbe PCR Kit Roche 
miRNeasy Micro Kit Quiagen 
Qiamp DNA Blood Mini Kit Quiagen 
QuantiTect SYBR Green RT-PCR Kit Quiagen 
Rneasy Mini Kit  Quiagen 
2.6 Antibodies for flow cytometry 
All Antibodies used in this study were anti-human antibodies and stored at 4 °C. The 
concentrations applied for the antibodies utilized in this study are summarized in 
table 2.1. 
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Table 2.1: Fluorochrome conjugated antibodies for flow cytometry 
Specificity  Fluorochrom 
Concentration; 
μl/ 106 cells 
Company  
Blue Viability Dye UV exitation 1 Invitrogen  
CD1d 
Allophycocyanin 
(APC) 
0.125 µg/µl     
1 
eBiosiences  
CD3 Pacific Blue 
0.2 µg/µl           
2 
Becton Dickinson 
CD3  
Phycoerythrin 
(PE) 
2 Becton Dickinson 
CD14 Pacific Blue 
0.2 µg/µl           
2 
Becton Dickinson 
CD16 
APC-Cyanine7 
(APC Cy7)  
2 Becton Dickinson 
CD19 Pacific Blue 2 Becton Dickinson 
CD56 PE-Cy7 2 Becton Dickinson 
CD57 
(Fluorescein 
isothiocyanate) 
FITC 
0.2 µg/µl           
1 
eBiosiences  
CD107a Alexa 700 
1 µg/µl              
2 
Becton Dickinson 
CD127 FITC 
0.025 µg/µl       
1 
eBiosiences  
HLA-E PE 
0.1 µg/µl           
1 
eBiosiences  
IFN-γ FITC 
0.1 µg/µl           
1 
eBiosiences  
IFN-γ PerCP Cy5.5 
0.012 µg/µl       
5 
eBiosiences  
KIR2DL3 FITC 
0.025 µg/µl       
5 
R&D Systhems  
KIR2DL3 PE 10 R&D Systhems  
Mouse IgG1 Iso Control  PE 1 R&D Systhems  
Mouse IgG2A Iso Control  FITC 5 R&D Systhems  
NKG2A APC 5 Beckman coulter 
NKG2A PE 5 Beckman coulter 
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NKG2C PE 
0.025 µg/µl       
5 
R&D Systhems  
Vα24 FITC 5 Beckman coulter 
Vβ11 APC 5 Beckman coulter 
    
    
CD1d Tetramer  APC 0.2 ProImmune 
CD1d Tetramer Iso control APC 0.2 ProImmune 
 
2.7 Consumables and Equipment 
Cell culture flasks, T25, T75 Greiner Bio-One 
Cell culture plates (6-, 12-, 24-, 48-, 96-well) Greiner Bio-One 
Centrifuge 5415C Eppendorf 
Centrifuge 5415R Eppendorf 
Cryo tubes, 2.0 ml   Greiner Bio-One 
EasySep purple magnet Stemcell technologies  
Glomax multi detection system  Promega  
KX-21N Sysmex 
LeucosepTM tubes, 50 mL Greiner Bio-One 
Liaison XL DiaSorin 
LightCycler 2.0 Roche 
Megafuge 1.0R Heraeus 
Megafuge 40R Thermo Scientific 
Microscope Primo Vert Zeiss 
Microscope TMS Nikon 
Mr. Frosty freezing container  Thermo Scientific 
Polystyrene round-bottom tubes, 5 mL   BD Falcon™ 
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Flow cytometer  
FACS Calibur  Becton Dickinson 
FACS Canto II Becton Dickinson 
LSR II Becton Dickinson 
 
2.8 Software and Webpages 
FlowJo 7.6 Tree Star, Inc. 1997-2008 
GraphPad Prism GraphPad Software, Inc 
Microsoft Office Microsoft 
3 Methods 
3.1 Cell culture 
3.1.1 Thawing of cells  
One vial of frozen cells (K562, K562 HLA-E, P815, LCL721.221) was taken out of the 
liquid nitrogen and quickly thawed in a 37 °C water bath. The cells were then 
resuspended in 10 mL PBS and centrifuged at 528 xg for 7 min. After the washing 
step the cells were taken up in 20 mL of the appropriate media and placed into a T75 
cell culture flask.  
3.1.2 Passaging of suspension cells 
Suspension cells (K562, K562 HLA-E, P815, LCL721.221) were thoroughly 
resuspended and placed into the new flask in the designated concentration.  
3.1.3 Freezing of cells 
Cells were washed in 10 mL PBS and centrifuged at 528 xg for 7 min. The 
supernatants were removed and the cells were transferred to a cryo tube in 1 mL 
freezing medium (FCS containing 10% DMSO). The cryo tubes were transferred to a 
Mr. Frosty freezing container filled with isopropanol and kept at -80 °C over night 
allowing a temperature drop of approximately 1 °C/min. The cells were transferred to 
liquid nitrogen the following day. 
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3.2 Immunological Methods 
3.2.1 Isolation of PBMCs (peripheral blood mononuclear cell) from peripheral 
blood 
To isolate PBMCs from peripheral blood Ficoll density centrifugation was used. 
Differential migration during centrifugation results in the separation of cell types into 
different layers. The bottom layer contains Ficoll-aggregated red blood cells. 
Immediately above is a diffuse layer containing mostly granulocytes and unbound 
Ficoll. Due to a slightly lower density, the lymphocytes sediment at the interface 
between the Ficoll and uppermost plasma layer. 
 
For PBMC isolation 15 mL of Biocoll Separating solution was transferred to a 50 mL 
Leucosep tubes and centrifuged for 1 min at 367 xg to allow the separating solution 
to pass through the filter. Afterwards 30 mL of blood were carefully placed in the tube 
and centrifuged for 10 min at 790 xg. After centrifugation the upper layer, containing 
lymphocytes and granulocytes, was transferred to a fresh 50 mL Falcon tube and 
washed in a total volume of 40 mL PBS. The cells were centrifuged at 652 xg for 
8 min. After two additional washing steps the cells were transferred to freezing 
medium and placed in a Mr. Frosty freezing container at -80°C. The cells were 
transferred to liquid nitrogen the following day.      
3.2.2 Flow cytometric identification and characterization of NK cells 
Frozen PBMCs were removed from the liquid nitrogen tank and quickly thawed in a 
37 °C water bath and taken up in 10 mL PBS. After three washing and centrifugation 
steps (528 xg; 7 min) PBMCs were counted using the KX-21N cell counter. 1*106 
PBMSs were transferred to Polystyrene round-bottom tubes and centrifuged at 
367 xg for 5 min. Subsequently the cells were stained for 15 min at room temperature 
using 1 µl Blue viability dye and 1 mL PBS per tube. After an additional washing step 
the cells were stained with fluorochrome-conjugated antibodies against cell surface 
proteins. To identify NK cells, PBMCs were stained with Pacific Blue labeled 
antibodies against CD3, CD14 and CD19, allowing the exclusion of T cells, 
monocytes and B cells. PMBCs were further stained with antibodies against CD16 
(APC-Cy7) and CD56 (PE-Cy7) allowing further characterization of NK cells. 
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Additional fluorochrome-conjugated antibodies against surface proteins were added 
according to requirements. A master mix containing all antibodies of interest was 
prepared and equally distributed to each sample. The antibody cell mix was allowed 
to incubate at room temperature for 15 min. After incubation cells were washed using 
PBS and fixated at room temperature for 15 min using 100 µl IC Fixation Buffer per 
tube. Fixated cells were washed with PBS and analyzed using a LSRII flow 
cytometer. 
3.2.3 Flow cytometric functional characterization of NK cells 
To test NK cell functionality, frozen PBMCs were removed from the liquid nitrogen 
tank and quickly thawed in a 37 °C water bath and taken up in 10 mL PBS. After 
three washing and centrifugation steps (528 xg; 7 min) PBMC were counted using 
the KX-21N cell counter. 1*106 PBMCs were transferred to Polystyrene round-bottom 
tubes. 
 
In parallel NK cell target cells (K562, K562 HLA-E, 221) were washed three times 
with PBS and brought to a concentration of 1*106 cells/mL PBS. P815 cells were 
washed and incubated with p815-specific antibody at 1mg/mL for 30 min. After an 
additional washing step to remove unbound antibody, cells were brought to a 
concentration of 1*106 cells/mL PBS. 100 µl of target cell solution was transferred to 
the PBMC containing Polystyrene round-bottom tubes to establish an effector target 
ratio of 1:10. After centrifugation the supernatants were removed and the cells were 
resuspended in 1 mL R10, containing 10 ng/mL Brefeldin A and 2 µl AlexaFlour700 
labeled CD107a specific antibody. 
 
After incubation for 5 h at 37 °C the cells were stained using Blue Viability dye for 
15 min at room temperature and washed with PBS. The cell suspension was than 
incubated with antibodies against surface proteins (15 min, room temperature) 
washed with PBS and subsequently fixated. After fixation the cells were washed 
twice with 1x Permeabilization Buffer. After permeabilization PBMCs were stained for 
intracellular IFN-γ, previously retained by Brefeldin A, using IFN-γ specific antibody 
label with FITC or PerCP Cy5.5. The cells were incubated for 15 min at room 
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temperature. After incubation cells were washed with PBS and analyzed using a 
LSRII flow cytometer. 
3.2.4 Enrichment of NK cells   
PBMCs were taken out of the nitrogen tank and thawed as described above. Cells 
were counted using the KX-21N cell counter and 1*108 PBMCs at a concentration of 
5*107 cells/mL (2 mL) in PBS containing 2% FCS were used to isolate NK cells with 
the Stemcell Technologies EasySep™ Human NK Cell Enrichment Kit. In accordance 
with the provided protocol 100 µl of EasySep™ Human NK Cell Enrichment Cocktail 
was added to the cell suspension and incubated at room temperature for 10 min. 
Subsequently 200 µl of vortexed EasySep™ Magnetic particles were added and 
incubated at room temperature for 10 min. After that the Polystyrene round-bottom 
tube containing the suspension was transferred to the EasySep™ Magnet and 
incubated for 2.5 min. After incubation the contents of the tube was poured into a 
fresh 15 mL falcon tube, with the tube remaining in the magnet during the procedure. 
This ensured that only NK cells were transferred to the new tube, while the non-NK 
cells were held back magnetically. The empty tube was refilled with 2.5 mL PBS 
containing 2% FCS and the procedure was repeated twice. The number of NK cell 
enriched cells was assessed using the KX-21N cell counter. The tube containing the 
non-NK cells was discarded.  
 
3.2.5 Enrichment of NKG2A positive NK cells  
NKG2A positive NK cells were enriched using the Stemcell Technologies EasySep™ 
Human PE Positive Selection Kit. In accordance with the provided protocol the 
previously prepared NK cell enriched cells were centrifuged at 528 xg for 5 min. After 
discarding the supernatant the cells were resuspended in 100 µl PBS containing 
2% FCS and incubated with 10 µl species-specific FcR blocking antibody and PE 
labeled NKG2A specific antibody (5 µl/ 1*106 cells). After 15 min of incubation, 20 µl 
of Easy Sep PE Selection Cocktail were added and incubated for 15 min. 
Subsequently 10 µl of resuspended EasySep Magnetic Nanoparticles were added 
and incubated for 10 min. In the next step the Polystyrene round-bottom tube was 
transferred to the EasySep™ Magnet and incubated for 5 min. After incubation the 
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contents of the tube was poured into a fresh 15 mL falcon tube, with the tube 
remaining in the magnet during the procedure, ensuring that the magnetically labeled 
NKG2A positive cells remained in the tube while the NKG2A positive cell depleted 
fraction was transferred to the new tube. Afterwards the tube was refilled with 2.5 mL 
PBS containing 2% FSC and the procedure was repeated twice. After the third 
separation step the magnetically labeled NKG2A positive cells were resuspended in 
7.5 mL PBS and the cell numbers of the NKG2A positive and negative fraction was 
assessed using the KX-21N cell counter. All incubation steps were carried out at 
room temperature. 
3.2.6 Treatment of primary human hepatocytes (PHHs) with IFN-α 
PHHs were obtained from the Department of Gastroenterology and Hepatology at the 
University Hospital Essen. When received, cells were seeded in 24-well plates, each 
well containing 500.000 cells in 500 µl medium. The cells were treated with 
100 IU/mL IFN-α for a period of 24 h. Untreated controls were incubated with medium 
alone. After 24 h medium was removed and the adherent PHHs were washed twice 
with sterile PBS. Afterwards each well was treated with 200 µl trypsin for 2 min at 
37 °C. The no longer adherent cells were taken up in 500 µl PBS per well and 
transferred to Polystyrene round-bottom tubes and centrifuged at 367 xg for 5 min. 
The supernatants were removed. For staining, untreated cells or cells treated with 
IFN-α from four wells were pooled and incubated with 1 µl HLA-E specific antibody 
labeled with PE for 15 min at room temperature. After incubation cells were washed 
using PBS and fixated at room temperature for 15 min using 100 µl IC Fixation 
Buffer. Fixated cells were washed with PBS and analyzed using a FACS Calibur flow 
cytometer.      
3.2.7 Induction of HLA-E expression on K562 HLA-E cells 
K562 HLA-E cells were incubated with 100 µmol/L core35-44 peptide (amino acid 
sequence: YLLPRRGPRL) at 28 °C over night. HLA-E expression was assessed 
using flow cytometry. The cells were stained using a PE labeled HLA-E specific 
antibody for 15 min at room temperature, washed and fixed using 100 µl IC Fixation 
Buffer. Fixed cells were washed and resuspended in PBS. Analysis was performed 
using a FACS Calibur flow cytometer. 
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3.3 Microarray analysis of HLA-E expression in liver tissue from HCV- and 
HBV-infected patientsa 
Microarray analysis was carried out by the Department of Gastroenterology and 
Hepatology at the University Hospital Essen.   
 
Liver biopsies from 51 patients with chronic HCV and from 22 patients with HBV 
infection were collected in the Department of Gastroenterology and Hepatology at the 
University Hospital Essen. All diagnostically indicated needle biopsies were taken 
within the PROFILE biomarker project (Kohl et al. 2013) Briefly, 5 to 8 mg liver tissue 
were homogenized with the TissueRuptor in QIAzol Lysis Reagent to isolate total 
RNA using the miRNeasy Micro Kit according to the protocols of the manufacturer. 
RNA integrity was determined on the Experion Automated Electrophoresis System 
using the Experion RNA StdSens Analysis Kit. RNA samples were preprocessed with 
the 3‟ IVT Express Kit and then hybridized on Human Genome U219 16-Array Plates 
using the GeneTitan MC Instrument according to the manufacturer‟s instructions. 
Robust multi-array average (RMA) normalization and data analysis was carried out 
with the Expression Console Software (version 1.2.1, Affymetrix).  
3.4 Isolation and stimulation of primary human hepatocytes and analysis of 
HLA-E expression 
Isolation and stimulation of primary human hepatocytes was carried out by the 
Department of Gastroenterology and Hepatology at the University Hospital Essen. 
Primary human hepatocytes were isolated from resected liver tissue as previously 
described by (Zhang et al. 2012).Briefly, liver tissue was perfused and digested using 
two-step-collagenase-perfusion. First EGTA (0.5 mM) resolved into HBSS (Hanks 
balanced salt solution) and second CaCl2 (5 mM)and collagenase (0.5 mg/mL) 
dissolved in HBSS were used for digestion to dispense the cells. Hepatocytes were 
enriched by centrifugation steps at 50 xg and seeded into collagen-I-coated culture 
plates using DMEM Ham‟s F12 supplemented with 10% FCS, 1% L-glutamine und 
0.08 U/mL penicillin/streptomycin. Two days post preparation PHH were stimulated 
with 50 µg/mL poly I:C for 6 h. Total RNA was extracted and purified using the 
Qiazol™ and the Rneasy Mini Kit. Quantitative RT-PCR was performed with the 
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QuantiTect SYBR Green RT-PCR Kit using 0.1 to 0.3 µg of total RNA. Gene 
expression of HLA-E was determined using a comercially available primer set 
(Qiagen, Cat. No. QT00056567). The calculated copy numbers were normalized to  
β-actin, detected with forward 5´-TCCCTGGAGAAGAGCTACGA-3´ and reverse 
primer 5´-AGCAATGTGTTGGCGTA-CAG-3´. 
3.5 Analysis of KIR genotype 
KIR genotyping was carried out by the Department of for Transfusion Medicine at the 
University Hospital Essen. 
Unlike classical human leukocyte antigens (HLA) the relevant polymorphism of Killer 
Cell Immunoglobulin-like receptors (KIR) is spread over the entire length of the KIR 
genes. Therefore, separate PCR amplifications of all exons are needed for low 
resolution KIR typing, which determines presence or absence of specific KIR genes 
in a sample. DNA of patients was extracted from PBMCs using spin columns. The 
KIR were genotyped using sequence-specific oligonucleotides on a Luminex™ flow 
 nalyser platform (Heinemann 2009). In brief, this methodology consisted of a set of 
reverse oligonucleotide probes conjugated to fluorescently coded microspheres. 
Each DNA was amplified using three separate group-specific biotinylated primer sets 
targeting all KIR gene exons. PCR products were subsequently denatured and 
allowed to hybridize to complementary DNA oligonucleotide probes. Bound 
amplicons were tagged with  nalyser din-phycoerythrin. The assignment of KIR 
genotypes was based on the reaction pattern determined by the Luminex™ flow 
 nalyser using specific software (HLA Fusion, One Lambda, Inc.). Finally, all KIR 
genotypes were checked for consistency using all known KIR haplotypes on the 
Allele Frequency Net Database (www.allelefrequencies.net) (Gonzalez-Galarza et al. 
2011). This database comprises approximately 300 different KIR genotypes found in 
more than 12,000 individuals from multiple populations. Based on the individual set 
of KIR genes in a sample the A KIR or B KIR haplotypes were assigned. 
3.6 IFNL3 (IL-28B) and HLA class I genotyping 
Genomic DNA was extracted from PBMCs using the QIAmp Blood Kit. IL28B 
rs12979860 genotyping was performed using a LightSNiP Typing Assay and the 
LightCycler FastStart DNA MasterPLUS HybProbe PCR Kit on a LightCycler 2.0 
Methods 
 
 
36 
 
Instrument . The amplification protocol consisted of an initial denaturation step of 
95  C for 10 min followed by 45 cycles of 95 °C for 10 s, 60 °C for 10 s and 72 °C for 
15 s and subsequent melting curve analysis. HLA-A and HLA-B typing at two-digits 
resolution-level was performed using sequence-specific primers methodology or 
alternatively using sequence-specific oligonucleotides (Oudshoorn et al. 2007). 
3.7 Diagnostic methods 
CMV status of 391 IDUs was analyzed using Liaison XL and the DiaSorin LiaisonTM 
CMV IgG II kit.      
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4 Results 
4.1 Patients 
A total of 68 subjects were enrolled in this study, including 58 patients with a history 
of injection drug use (IDU) and 10 healthy controls (H). All IDUs were recruited at the 
Rheinische Kliniken (Clinic for addictive behavior and drug abuse) Essen. 19 anti-
HCV negative (by CMIA) subjects with undetectable HCV-RNA (by RT-qPCR with a 
detection limit of 15 IU/ml) reporting frequent illicit intravenous drug use were 
considered to be exposed to HCV without getting infected (HCV seronegative IDU; 
SN). 19 subjects were chronically infected with HCV genotype 1, 3 or 4 (CH). 
Additional 20 anti-HCV positive IDUs with undetectable HCV-RNA were included and 
were considered as patients who had spontaneously resolved infection I. All 
individuals were treatment naïve. 10 anti-HCV negative healthy individuals were 
included as controls.  
 
Specific host genetic markers influence HCV infection outcome. Therefore, the 
subjects enrolled in this study were analyzed for their KIR2DL3 and IFNL3 genotype. 
A single nucleotide polymorphism near the IFNL3 region (rs12979860) encoding 
interferon-λ3 was identified as a strong predictor for HCV infection outcome and 
treatment response in HCV genotype 1 infection. Specifically, patients with the IFNL3 
C/C genotype are more likely to resolve HCV infection than patients with the IFNL3 
C/T or T/T genotype (reviewed in (Berger et al. 2012)). Although the number of 
patients is not sufficient for a robust analysis, in our patient groups we did not 
observe a trend towards enrichment of the protective IFNL3 genotype in the group of 
IDUs without HCV infection. In fact, 58% of chronically HCV infected IDUs and 58% 
of IDUs with resolved infection displayed the protective IFNL3 C/C genotype while 
only 40% of seronegative IDUs had the protective genotype. Similar to IFNL3, 
homozygosity for the NK cell receptor KIR2DL3 gene in combination with 
homozygosity for its ligand HLA-C1 group alleles has been associated with favorable 
HCV infection outcome (Khakoo et al. 2004) and resistance to HCV infection (Knapp 
et al. 2010). Strikingly, 74 % of seronegative IDUs enrolled in this study were 
KIR2DL3 homozygous while only 44-45% were KIR2DL3 homozygous in the other 
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groups. Although again the cohort size is underpowered for a robust analysis, in line 
with previous data we observed enrichment of the favorable KIR/KIR-ligand genotype 
in HCV seronegative IDUs.  
 
As risk behavior is also associated with the likelihood to acquire HCV infection 
(Pouget et al. 2012), we included the median duration of injection drug use in the 
patient characteristics. While seronegative IDUs and IDUs with resolved HCV 
infection reported similar median durations of intravenous drug use (R: 8.6 (1-25) 
years; SN: 6.7 (2-14) years), we noted a longer history of injecting drugs in 
chronically HCV infected patients (CH: 15.3 (2-39) years). Patient group 
characteristics are summarized in table 4.1. 
 
Table 4.1: Study subjects 
 Chronics Resolved Seronegative Healthy 
n 19 20 19 10 
Age (mean)  37 36 32 32 
% male 74 90 74 40 
% KIR2DL3 homozygous 44 45 74 45 
% IL28B C/C genotype 58 60 40 n.d. 
median duration of IDU 
15.3 years  
(2-39) 
8.6 years  
(1-25)  
6.7 years  
(2-14) 
0 
n.d. not done 
4.2 Phenotypic characterization of NK cells of chronically HCV infected IDUs 
and seronegative IDUs 
NK cells are a major player in innate immunity and early immune responses in viral 
infections. In HCV infection distinct NK cell phenotypes have been repeatedly 
associated with specific outcome. We therefore decided to comparatively analyze NK 
cells of seronegative IDUs and chronically HCV infected IDUs to characterize a 
potentially protective NK cell phenotype in seronegative IDUs. NK cells are defined 
as CD3- CD14- and CD19- lymphocytes and can be further subdivided based on the 
expression of CD16 and CD56.  By flow cytometric analysis we identified 
lymphocytes (Figure 4.1A) and excluded dead cells (Figure 4.1B). In the next step T 
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cells (CD3), monocytes (CD14), and B cells (CD19) (Figure 4.1C) and subsequently 
doublets were excluded (Figure 4.1D). The remaining cells were analyzed for the 
expression of CD56 and CD16 and subdivided into CD56brightCD16-, CD56dimCD16+ 
and CD56negCD16- NK cells (Figure 4.1E).   
 
 
 
We analyzed the expression of a broad panel of NK cell receptors including members 
of to the C-type lectin like receptor family (NKG2A, NKG2C, NKG2D), the natural 
cytotoxicity receptor family (NKp30, NKp46) and the Killer cell Ig-like (KIR) receptor 
family (KIR2DL2, KIR2DS1, KIR3DL1, KIR2DL3, KIR2DL1) on NK cells of 20 
seronegative IDUs and 10 chronically HCV infected IDUs. All receptor analyses were 
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Figure 4.1: Gating strategy.  
To characterize NK cells using flow cytometry, (A) lymphocytes were identified and (B) dead cells excluded. (C) In 
the next step T cells (CD3), monocytes (CD14) and B cells (CD19) were gated out. (D) Subsequently single cells 
were identified and analyzed for the expression of CD56 and CD16 and subdivided into CD56
bright
CD16
+
 (purple), 
CD56
dim
CD16
+
 (red) or CD56
neg
CD16
+
 NK cells (orange).   
Results 
 
 
40 
 
performed on CD56brightCD16- and CD56dimCD16+ NK cells, apart from the KIR 
receptors as those are solely expressed on CD56dimCD16+ NK cells.   
 
Out of the eleven receptors tested NKG2C (uncorrected p=0.0236), NKp46 
(uncorrected p=0.0328) and KIR2DL3 (uncorrected p=0.0426) were expressed in 
significantly higher frequencies on CD56dim NK cells of seronegative IDUs than 
CD56dim NK cells from chronically infected IDUs (Figure 4.2). In addition, significantly 
decreased numbers of NKG2A+ CD56bright NK cells (uncorrected p<0.0001; Figure 
4.2) were observed in seronegative IDUs compared to chronically infected IDUs. 
Interestingly, the same trend was observed in CD56dim NK cells. 
4.3 Functional analysis of NK cells of chronically HCV infected IDUs and 
seronegative IDUs 
NK cells are regulated by a complex network of activating and inhibiting receptors. To 
analyze functional characteristics of NK cells of patients with different HCV infection 
status, three different NK cell target cell lines were used mediating NK cell activation 
or inhibition through different receptor ligand interactions. The majority of KIR 
receptors inhibit NK cell activation after binding to HLA molecules. To facilitate NK 
cell activation all target cell lines are HLA negative. K562 cells are frequently used to 
activate NK cells. They mediate activation via the activating NK cell receptor NKG2D 
by expressing its ligands ULBP-1/2 and MIC-A/B on their surface (Bae et al. 2012). 
For activation of NK cells by the natural cytotoxicity receptors NKp44 and NKp46, 
221 cells were used as NKp44 and NKp46 dependent lysis has been reported for this 
cell line (Pessino et al. 1998; Cantoni et al. 1999; Sivori et al. 1999). NK cells are also 
known to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) via the 
FcγRIII (CD16) receptor. This was mimicked by using antibody coated p815 cells as 
NK cell target cells. An overview of the used target cells and the engaged receptors 
are given in Figure 4.3.   
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Figure 4.3: Overview of used NK cell target cell lines.  
K562 cells activate NK cells by ligation of the activating NKG2A NK cell receptor. 221 cells activate NK cells by 
binding to NKp44 and NKp46. Antibody coated p815 cells activate NK cells FCγRIII (CD16) and are used to 
analyze antibody-dependent cell-mediated cytotoxicity.  
 
Expression of the degranulation and cytotoxicity marker CD107a (Alter et al. 2004), 
the cytokines IFN-γ and TNF-α and the chemoattractant MIP-1β was analyzed in NK 
cells of 20 seronegative IDUs and 10 chronically HCV infected IDUs in response to 
stimulation with K562 cells, 221 cells and antibody coated p815 cells.  
 
In line with the previously observed increased levels of NKp46pos NK cells in 
seronegative IDUs (Figure 4.2), we observed increased CD107a production of NK 
cells of seronegative IDUs in response to 221 cells (uncorrected p = 0.0165, Figure 
4.4). However, we could not observe differences in IFN-γ, TNF-α or MIP-1β 
production in response to 221 stimulation or other stimulations (Figure 4.4). 
 
 
 
221 NK
inhibitory
K562 NK
inhibitory
NKG2D
p815 NK
inhibitory
FcγRIII
NCR
NK cell activation by NKG2D
NK cell activation by natural cytotoxicity 
receptors NKp44 and NKp46 (NCRs)
NK cell activation by antibody-dependent 
cell-mediated cytotoxicity
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4.4 Seronegative IDUs are characterized by increased frequencies of 
KIR2DL3+NKG2A- NK cells 
As we observed a very pronounced difference in NKG2A expression between HCV 
seronegative IDUs and chronically infected IDUs and KIR2DL3 genotype has 
repeatedly been associated with HCV susceptibility and resolution (Khakoo et al. 
2004; Knapp et al. 2010), we decided to characterize NKG2A and KIR2DL3 
expression in IDUs in greater detail. For that purpose, NK cells of nineteen IDUs with 
chronic HCV infection (CH), twenty IDUs with resolved HCV infection I, nineteen 
seronegative (SN) IDUs and ten healthy controls (H) were identified and 
simultaneously stained for NKG2A and KIR2DL3. Individuals lacking the KIR2DL3 
gene were excluded from the analysis. A representative staining and the gating 
strategy are given in Figure 4.5. As KIR2DL3 is almost exclusively expressed on 
CD56dim NK cells while NKG2A is expressed on up to 100% of CD56bright NK cells, 
CD56dim NK cells were used for the analysis. 
 
 
Figure 4.5: Gating strategy.  
NK cells were characterized as described above and KIR2DL3
-
NKG2A
+
, KIR2DL3
+
NKG2A
+
, KIR2DL3
+
NKG2A
- 
and KIR2DL3
-
NKG2A
-
 NK cells were identified. 
 
HCV seronegative IDUs had significantly increased frequencies of 
CD56dimKIR2DL3+NKG2A- NK cells (median: 16.8%) compared to IDUs with chronic 
HCV infection (median: 6.47%; p<0.0001), healthy controls (median 4.65%; p<0.001) 
and IDUs with resolved HCV infection (median 8.67; p<0.05; Figure 4.6A). In turn, 
analysis of CD56dimKIR2DL3-NKG2A+ NK cells revealed decreased frequencies in  
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HCV seronegative IDUs (median: 27%) compared to healthy controls (median: 52.1; 
p<0.001) and IDUs with chronic HCV infection (median: 48.5%; p<0.001; Figure 
4.6B). Interestingly, IDUs with resolved HCV infection had intermediate frequencies 
ranging between HCV seronegative IDUs and IDUs with chronic HCV infection 
(median 37.1%; Figure 4.6B). The combination of increased levels of 
KIR2DL3+NKG2A- NK cells and decreased levels of KIR2DL3-NKG2A+ NK cells in 
seronegative IDUs suggested a negative correlation between KIR2DL3 and NKG2A 
expression. Indeed, an analysis of CD56dim NK cells of all patients revealed a strong 
inverse correlation between the frequency of KIR2DL3+ and NKG2A+ NK cells 
(p<0.0001, r=-0.5341; Figure 4.6C). 
4.5 NKG2C expression correlates with NKG2A and KIR2DL3 expression 
NKG2A and NKG2C are both members of the C-type lectine like NK cell receptor 
familiy, forming heterodimers with CD94 on the cell surface. Both receptors bind to 
the same lignd, HLA-E, with different affinities and mediate different signals to NK 
cells. NKG2A binds HLA-E with higher affinity than NKG2C and mediates inhibiting 
signals to NK cells, while NKG2C binds HLA-E with low affinity and is an activating 
NK cell receptor (Aldrich et al. 1994; Borrego et al. 1998). As it has previoulsy been 
reported that NK cells expressing high levels of NKG2A express low levels of NKG2C 
and vice versa (Beziat et al. 2012), we analyzed NK cells of IDUs with different HCV 
infection status and healthy controls for NKG2C expression.  
 
An analysis including all patients independent of HCV infection status revealed an 
inverse correlation between NKG2A and NKG2C expression on CD56dim NK cells 
(p= 0.0056; r= -0.3926; Figure 4.7A). Interestingly, there was also a weak but 
statistically significant negative correlation bewteen NKG2C and KIR2DL3 expression 
(p= 0.0047; r=0.2179; Figure 4.7B). We did not observe significant differences in 
NKG2C expression in the different study groups, however a strong tendency towards 
increased frequencies of NKG2C+ NK cells in seronegtive IDUs and IDUs with 
resolved HCV infection was observable (Figure 4.7C). 
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Figure 4.6: HCV seronegative IDUs have increased frequencies of KIR2DL3
+
NKG2A
-
 CD56
dim
 NK cells.  
NK cells of healthy controls (H), seronegative IDUs (SN), IDUs with resolved HCV infection I and chronically HCV 
infected IDUs (CH) were analyzed. (A) SN had significantly higher frequencies of CD56
dim
KIR2DL3
+
NKG2A
-
 NK 
cells compared to H, CH and R. (B) SN had significantly lower frequencies of CD56
dim
KIR2DL3
-
NKG2A
+
 NK cells 
compared to H and CH (Kruskal-Wallis; ***p<0.001; *p<0.05). (C) In addition there was an inverse correlation 
between the frequency of CD56
dim
KIR2DL3
+
 and CD56
dim
NKG2A
+
 NK cells (p<0.0001; r=-0.5341). 
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Figure 4.7: NKG2C expression correlates with NKG2A und KIR2DL3 expression.  
NKG2C, NKG2A and KIR2DL3 expression on CD56
dim
 NK cells of IDUs with different HCV infection outcome 
were analyzed. (A) NKG2C and NKG2A expression was inversely correlated correlated (p= 0.0056; r= -0.3926). 
(B) NKG2C and KIR2DL3 expression was also correlated (p= 0.0047; r=0.2179). (C) A strong trend towards 
increased levels of NKG2C
+
 NK cells in seronegative IDUs and IDUs with resolved HCV infection was observed, 
however, the differences were not statistically significant. 
 
4.6  NK cell subset distribution and CD57 expression do not vary in between 
patients 
As KIR2DL3 and NKG2C are predominatly expressed on CD56dim NK cells and 
NKG2A is predominatly expressed on CD56bright NK cells, we analyzed the NK cell 
subset distribution among patients with different HCV infection outcome to explore 
the possibility that the KIR2DL3+NKG2A- NK cell phenotype observed in seroneagtive 
IDUs was a result of a different NK cell subset distribution. However, the analysis 
revealed that there was no difference in subset distribution in between patient groups 
(Figure 4.8A). To further define the maturation status, NK cells were analyzed for the 
expression of CD57. CD57 is reported to be expressed on previouly activated NK 
cells (Bjorkstrom et al. 2010; Lopez-Verges et al. 2010) and follows a specific 
expression pattern in CD56bright, CD56dim and CD56neg NK cells. In our analysis CD57 
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followed the pattern expected for the different NK cell subsets, however we could not 
observe a difference in CD57 expression between the different patient groups 
(Figure 4.8B). 
 
Figure 4.8: CD57 expression and subset distribution.  
NK cells of healthy controls (H), seronegative IDUs (SN), IDUs with resolved HCV infection I and chronically HCV 
infected IDUs (CH) were characterized and subset distribution and CD57 expression was analyzed. There was no 
difference in (A) subset distribution of CD56bright, CD56dim and CD56neg NK cells and (B) CD57 expression 
between patient groups. 
 
4.7 The NKG2A/NKG2C ligand HLA-E is upregulated in HCV infected livers 
Previous reports suggest a protective effect of homozygosity for KIR2DL3 and HLA-
C1 in HCV infection. However, a direct mechanism explaining conclusively how 
KIR2DL3 protects from HCV infection has never been described. In fact, it is 
counterintuitive that an inhibiting NK cell receptor is protective in HCV infection. Here 
we hypothesize that the protective effect is rather mediated by the absence of 
NKG2A than the presence of KIR2DL3. To further strengthen this hypothesis, we 
analyzed the intrahepatic expression of HLA-E, the ligand for the inhibiting NK cell 
receptor NKG2A and the activating NK cell receptor NKG2C.  
 
In cooperation with the Department of Gastroenterology and Hepatology at the 
University Hospital Essen, HLA-E expression profiles derived from liver biopsies were 
compared between 51 patients with HCV infection and 22 patients with Hepatitis B 
virus (HBV) infection. Expression of HLA-E was significantly higher in HCV infected 
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patients compared to HBV infected patients (p=0.002, Figure 4.9A). Interestingly, the 
data also revealed a positive correlation between HCV viral load and intrahepatic 
HLA-E transcript levels (p=0.0029; r= 0.3223; Figure 4.9B), while a similar analysis 
with HBV patients revealed no correlation (data not shown). Unlike HBV, HCV 
induces a strong type I interferon response in the infected liver which can be 
simulated by treatment with the TLR3 agonist poly I:C in vitro. Therefore, primary 
human hepatocytes were treated with 50 µl/ml poly I:C for 6 h and the HLA-E 
transcript level was determined by quantitative PCR. The results support that HLA-E 
mRNA levels are upregulated in response to poly I:C stimulation. On average a 2.9-
fold increase in HLA-E transcript levels was observed after poly I:C stimulation 
(p<0.0001; Figure 4.9C).  
 
Figure 4.9 The NKG2A ligand HLA-E is upregulated in HCV infected livers.  
(4) HLA-E transcript levels were determined in liver biopsies from patients with HCV infection and patients 
with HBV infection. HCV infected patients showed significantly higher HLA-E transcript signals compared 
to HBV infected patients (Mann-Whitney; p=0.002). (B) HCV viral load correlated with the HLA-E 
transcript signals (p=0.002; r= 0.3223). (C) PHHs were stimulated with 50 µl/ml poly I:C or medium for 6 
h. After treatment HLA-E RNA copy numbers were assessed by quantitative PCR. Poly I:C treated PHHs 
had significantly increased HLA-E RNA copy numbers compared to medium treated controls (paired t-
test; p<0.0001). (D) PHHs were treated with 100 IU/ml IFN-α or medium alone. After 24h HLA-E surface 
expression was analyzed using flow cytometry. IFN-α treated PHHs had significantly increased HLA-E 
levels (MFI) compared to untreated PHHs (paired t-test; p=0.013). 
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Taken together, there is strong evidence that HLA-E transcription is elevated in the 
liver upon infection with HCV. However, it is unclear if higher transcript levels result in 
higher HLA-E expression levels of the protein on the cell surface, because HLA-E 
needs to be stabilized by binding of leader peptide derived from other HLA 
molecules. We therefore addressed if treatment with IFN- directly affects HLA-E 
protein expression at the cell surface of primary human hepatocytes (PHH). HLA-E 
expression was analyzed by flow cytometry on PHH with and without prior IFN- 
treatment. Compared to the untreated control there was a significant upregulation of 
HLA-E on the cell surface of PHH in the presence of IFN- (p=0.013; Figure 4.9D).  
4.8 Induction of HLA-E expression on K562 HLA-E cells  
The previously described NK cell target cell lines do not express HLA-E and are thus 
not suited to analyze NK cell functionality in the context of HCV induced HLA-E 
expression. We therefore analyzed HLA-E expression on K562 cells stably 
transfected with HLA-E*01033 (K562 HLA-E cells). As Nattermann et al. previously 
described stabilization of HLA-E by external application of the HCV core35-44 peptide 
(Nattermann et al. 2005), we analyzed HLA-E expression on normal K562 cells and 
K562 HLA-E cells in the presence or absence of core35-44. In the presence of core35-
44, K562 HLA-E cells expressed high levels of HLA-E while only intermediate levels 
were expressed in the absence of the peptide (Figure 4.10A). K562 HLA-E cells were 
loaded with the core35-44 peptide at 28 °C over night. Assays assessing NK cell 
functionality are best carried out at 37 °C for a period of 5 h. We therefore tested the 
stability of HLA-E expression on K562 HLA-E cells at 37 °C over 5 h. While the cells 
expressed high levels of HLA-E directly after they were loaded with peptide at 28 °C, 
HLA-E expression rapidly declined at 37 °C. After one hour HLA-E expression was 
significantly reduced and after 2 h HLA-E expression was already barely detectable 
(Figure 4.10B). As K562 cells alone already expressed increased HLA-E levels and 
peptide induced HLA-E expression was instable at 37 °C, unloaded K562 HLA-E 
cells and K562 cells were used for the following experiments.  
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Figure 4.10: HLA-E expression by K562 and K562 HLA-E cells.  
HLA-E expression of K562 and K562 HLA-E cells was analyzed in the presence and absence of core35-44 peptide. 
(A) K562 HLA-E cells loaded with the core35-44 peptide displayed high levels of HLA-E on the cell surface while 
K562 HLA-E NK cells displayed intermediate HLA-E expression levels. (B) K562 HLA-E cells were loaded with 
core35-44 peptide at 28 °C over night and subsequently transferred to 37 °C. HLA-E expression decreased 
signifivantly after 1 h at 37 °C and was hardly detectable after 2 h.  
 
4.9 NKG2A enriched NK cells show a trend towards decreased degranulation 
in the presence of HLA-E 
As NK cells in seronegative IDUs are predominantly KIR2DL3+NKG2A- while NK cells 
in chronically HCV infected IDUs are predominately KIR2DL3-NKG2A+, NKG2A 
enriched and NKGA depleted NK cells of ten healthy individuals were comparatively 
analyzed. For that purpose, NK cells were enriched using an NK cell isolation kit 
allowing the enrichment of untouched NK cells. Subsequently, the NK cell enriched 
cell suspension was stained with a PE labeled NKG2A specific antibody and 
subdivided into an NKG2A enriched NK cell fraction and an NKG2A depleted NK cell 
fraction using a PE selection kit. For simplification the NKG2A enriched fraction will 
be referred to as the NKG2Apos NK cell fraction and the NKG2A depleted fraction will 
be referred to as the NKG2Aneg NK cell fraction. As HLA-E expression is upregulated 
in the HCV infected liver, we stimulated the NKG2Apos NK cell fraction and the 
NKG2Aneg NK cell fraction with K562 cells (HLA-E low) or K562 HLA-E cells (HLA-E 
high) (Nattermann et al. 2005). After 5 hours of stimulation CD107a expression was 
analyzed to assess degranulation. However we did not observe inhibition of 
NKG2Apos or NKG2Aneg NK cells in the presence of HLA-E (Figure 4.11A, B).  
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Figure 4.11: Functional analysis of NKG2A enriched and depleted NK cells. 
NK cells were enriched or depleted for NKG2A and stimulated with HLA-E high (K562 HLA-E) or HLA-E low 
expressing (K562) NK call target cells. (A) The NKG2A enriched fraction showed a trend towards inhibition in the 
presence of HLA-E high target cells (B) while NKG2A depleted NK cells were not inhibited in the presence of 
HLA-E. Wilcoxon matched pairs tests were used to compare groups and resulting p-values are indicated.  
  
4.10 HLA-E inhibits IFN-γ and CD107a production by KIR2DL3-NKG2A+ NK cells 
but not KIR2DL3+NKG2A- NK cells 
As NK cells might need the support of accesory cells to develope their full functional 
capacity, whole PBMCs from 10 healthy donors were stimulated with normal K562 
cells (HLA-E low) or K562 HLA-E cells (HLA-E high). IFN-γ production was 
significantly decreased upon stimulation with HLA-E expressing K562 cells compared 
to stimulation with native K562 cells in total NK cells (p= 0.0039; Figure 4.12A). As 
KIR2DL3+NKG2A- NK cells represent NK cells typically found in HCV seronegative 
IDUs and KIR2DL3-NKG2A+ NK cells represent NK cells typically found in chroncally 
HCV infected IDUs, those NK cell subtypes were further analysed using flow 
cytometry. KIR2DL3-NKG2A+ NK cells were efficiently inhibited in the presence of 
HLA-E expressing target cells (p=0.0039; Figure 4.12B) consistent with an inhibitory 
signal conferred by HLA-E. In contrast, no significant inhibition of IFN-γ production 
was observed in the KIR2DL3+NKG2A- NK cell subset (Figure 4.12C), which is the 
NK cell phenotype predominantly observed in HCV seronegative IDUs. The same 
results were obtained when the degranulation marker CD107a was analyzed in the 
different NK cell subsets in the absence and presence of HLA-E (Figure 4.12D-E).  
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Figure 4.12: KIR2DL3
+
NKG2A
-
 NK cells are inhibited in the presence of HLA-E. 
PBMCs of healthy individuals were stimulated with HLA-E low or high expressing NK cell target cells and CD107a 
and IFN-γ production by different NK cell subtypes was analyzed. (A) IFN-γ production by bulk NK cells and (B) 
KIR2DL3
-
NKG2A
+
 NK cells is inhibited in the presence of HLA-E. (C) IFN-γ production by KIR2DL3
+
NKG2A
-
 NK 
cells was not inhibited in the presence of HLA-E. (D-E) Similar results were obtained, when CD107a expression 
was analyzed. Wilcoxon matched pairs tests were used to compare groups and resulting p-values are indicated.  
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4.11 HLA-E inhibits IFN-γ production by NK cells of chronically HCV-infected 
IDUs but not by NK cells of seronegative IDUs 
As KIR2DL3+NKG2A- NK cells of healthy individuals were not inhibited in the 
presence of HLA-E, while KIR2DL3-NKG2A+ NK cells were potently inhibited, we next 
tested fuctionality of NK cells of seronegative IDUs and chronically HCV infeceted 
IDUs in the presence and absence of HLA-E directly. For that purpose PBMCs of ten 
chronically HCV infected IDUs and 10 seronegative IDUs were incubated with K562 
and K562 HLA-E NK cell target cells at an effetctor:target ratio of 10:1 and IFN-γ 
productions of NK cells was analyzed using flow cytometry. IFN-γ production by NK 
cells from chonically HCV infected IDUs was significantly inhibited in the presence of 
HLA-E (p=0.0017, Figure 4.13A), while there was no inhibitory effect on IFN-γ 
production by NK cells from HCV seronegative IDUs (Figure 4.13B). 
 
Figure 4.13: NK cells of chronically HCV infected IDUs but not seronegative IDUs are inhibited in the 
presence of HLA-E. 
PBMCs of chronically HCV infected and seronegative IDUs were stimulated with HLA-E high and low expressing 
NK cell target cell lines. (A) NK cells of chronically HCV infected IDUs were inhibited in the presence of HLA-E (B) 
while NK cells of seronegative IDUs were not inhibited by HLA-E. Wilcoxon matched pairs tests were used to 
compare groups and resulting p-values are indicated 
  
4.12 The Human cytomegalovirus (HCMV) serostatus has an impact on the NK 
cell phenotype of IDUs 
Human cytomegalovirus infects all human populations with a prevalence ranging 
from 50 %-100 % depending on socioeconomic factors (Dowd et al. 2009) and has 
previously been described to leave a stable imprint in the NK cell population. 
Productive HCMV infection results in a persistent increase of NKG2C+ NK cells 
displaying KIR receptors specific for HLA class I molecules (Muntasell et al. 2013). 
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Moreover, an expansion of KIR2DL3+NKG2C+ NK cells has been described as a 
result of HCMV infection (Beziat et al. 2012). Taken together, the existing data 
suggest that the phenotype of NK cells of HCMV seropositive individuals is 
reminiscent of the NK cell phenotype we describe for HCV seronegative IDUs. We 
therefore analyzed the NKG2A; NKG2C and KIR2DL3 expression on NK cells of anti-
HCMV positive and negative IDUs.  
 
Indeed, we observed a trend towards higher frequency of NKG2C+ and KIR2DL3+ NK 
cells in anti-CMV positive IDUs compared to anti-CMV negative IDUs 
(Figure 3.14A, B). Importantly we observed significantly decreased frequencies of 
NKG2A+ NK cells in anti-CMV positive IDUs (mean: 37.3%) compared to anti-CMV 
negative IDUs (mean: 51.2%; p= 0.0016; Figure 4.14C).  
 
 
Figure 4.14: Phenotypical analysis of NK cells of anti-HCMV positive and negative IDUs. 
NK cells of anti-HCMV positive and HCMV negative IDUs were analyzed for the expression of NKG2C; NKG2A 
and KIR2DL3. (A) Anti-HCMV positive IDUs showed a trend towards increased levels of NKG2C
+
 NK cells. (B) 
Frequencies of NKG2A
+
 NK cells were significantly decreased in anti-CMV positive IDUs (t-test; p=0.0016) (C) 
while they displayed a trend towards increased frequencies of KIR2DL3 expressing NK cells. 
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4.13 Human cytomegalovirus (HCMV) infection potentially influences HCV 
infection outcome 
We hypothesized that anti-CMV positive patients are enriched in the group of IDUs 
with resolved HCV infection and the group of HCV seronegative IDUs. To analyze 
this, we tested a total of 391 IDUs, 253 chronically HCV infected, 92 with resolved 
HCV infection and 46 seronegative IDUs for HCVM specific Immunoglobulin G (IgG). 
While only 52% of chronically HCV infected IDUs were HCVM seropositive, 60% of 
IDUs with resolved HCV infection and 59% of HCV seronegative IDUs tested positive 
for HCMV specific IgG (Figure 4.15A), however, the difference was not statistically 
significant. As HCMV prevalence is known to increase with age (Lubeck et al. 2010) 
we compared the median age of 67 HCV seronegative, 189 IDUs with chronic HCV 
infection and 87 IDUs with resolved HCV infection,. In fact HCV seronegative IDUs 
were significantly younger than IDUs with chronic (p<0.01) or IDUs with resolved 
HCV infection (p<0.01; Figure 4.15B). The median age of seronegative IDUs was 
33.8 years, in contrast, the median age of IDUs with chronic infection was 38.0 years 
and the median age of IDUs with resolved HCV infection was 38.3 years. The trend 
towards higher HCMV seroprevalence in the significantly younger group of HCV 
seronegative IDUs is unexpected and may in fact be biologically relevant for 
maintenance of the HCV seronegative state.  
 
 
Figure 4.15: Anti-HCMV prevalence and age in IDUs with different HCV infection outcome.  
52% of chronically HCV infected IDUs, 60% of IDUs with resolved HCV infection and 59% of HCV seronegative 
IDUs tested positive for HCMV specific IgG. (B) The age of 67 HCV seronegative IDUs, 189 chronically HCV 
infected IDUs and 87 IDUs with resolved HCV infection was compared. HCV seronegative IDUs are significantly 
younger than IDUs with chronic (p<0.01) of resolved infection (p0.1). 
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5 Discussion 
5.1 NK cells in HCV infection 
While several factors including IFLN3 genotype (Ge et al. 2009; Suppiah et al. 2009; 
Tanaka et al. 2009; Rauch et al. 2010) and vigorous early T cell responses (Lechner 
et al. 2000; Thimme et al. 2001; Urbani et al. 2002) are known to influence 
spontaneous resolution of HCV infection those factors do not mediate initial 
protection from infection. Little is known about the mechanisms resulting in resistance 
to HCV infection, however several reports indicate that NK cells might play a central 
role (Golden-Mason et al. 2010; Knapp et al. 2010; Werner et al. 2013). Here, we 
explored a large panel of NK cell receptors in a cohort of HCV seronegative IDUs 
with continuous risk behavior and compared their NK cell receptor expression profiles 
to IDUs with chronic HCV infection. Interestingly HCV seronegative IDUs showed 
higher frequencies of KIR2DL3+, NKG2C
+ and NKp46+CD56dim NK cells and lower 
frequencies of NKG2A+CD56bright NK cells compared to IDUs with chronic HCV 
infection.  
 
In line with the increased NKp46 expression in seronegtive IDUs in this inicial screen, 
we observed increased CD107a production by NK cells in response to 221 NK target 
cells, activating NK cells via NKp44 and NKp46. This data conclusively demonstrates 
increased NKp46 mediated fuctionality of NK cells in seroneagtive IDUs. While there 
is no data linking NKp46 expression to protection from HCV infection, there are 
reports that convincingly linked NKp46 to increased NK cell function in HCV infection. 
Kramer et al. identified NKp46dim and NK46high NK cells based on the density of 
NKp46 surface expression and coexpression of maturation markers. Importantly they 
were able to show that NKp46high NK cells displayed increased functionality in regard 
to cytolytic activity and IFN-γ production in general and in response to the HCV 
replicon system. Intrahepatic NK cells displayed the same phenotype, and the 
frequency of intrahepatic NKp46high NK cells was inversely correlated with HCV-RNA 
levels and fibrosis stage (Kramer et al. 2012). Taken together our data and the data 
by Kramer et al. indicate a beneficial effect of increased NKp46 levels in protection 
from HCV infection and viral control associated with increased NK cell functionality. 
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However, the question which ligand mediates this NKp46 mediated activation in HCV 
infection remains elusive. NKp46 is known to directly bind to viral antigens of 
influenza viruses (Mandelboim et al. 2001), however, an HCV specific ligand is 
unknown. Interestingly NKp44, was reported to bind to the E2 protein of other 
Flaviviruses (Dengue and West Nile Virus) (Hershkovitz et al. 2009), suggesting that 
NCR might also be able to directly bind to HCV E proteins.    
 
A study on HCV negative high-risk IDUs by Golden-Mason et al. analyzed expression 
of the natural cytotoxicity receptors NKp30 and NKp44 in a prospective cohort of 
IDUs with subsequent HCV genotype 1a infection and patients who remained 
seronegative (Golden-Mason et al. 2010). The authors observed higher expression 
levels of NKp30 associated with increased cytotoxicity in IDUs who remained HCV 
seronegative, however, no analyses of other NK cell receptors were performed. In 
our cohort of IDUs there was a minor trend towards higher expression of NKp30 in 
HCV seronegative IDUs, although the difference was not statistically significant. One 
important difference between the two study cohorts is the HCV genotype distribution. 
In North America IDUs are almost exclusively infected with HCV genotype 1a (Cox et 
al. 2005; Rustgi 2007) whereas in Germany infections with HCV genotype 1a, 1b and 
3a are common (Ross et al. 2000; Esteban et al. 2008). We therefore included in our 
cohort IDUs with HCV genotype 1 and 3 infections. In fact, there is strong 
immunological evidence that most IDUs are exposed to both genotypes (Giugliano et 
al. 2009). It seems possible that the protective effect of NKp30 is HCV genotype-
dependent and predominantly operative against genotype 1a.  
 
Although genetic association studies have repeatedly shown that the KIR2DL3 and 
HLA-C genotype have an impact on the outcome of HCV infection (Khakoo et al. 
2004; Knapp et al. 2010), to our knowledge this is the first study reporting increased 
protein expression of KIR2DL3 on NK cells of seronegative IDUs and IDUs with 
resolved infection. Of note, in line with these previous genetic association studies we 
also observed a higher frequency of HCV seronegative IDUs homozygous for 
KIR2DL3 compared to IDUs with chronic HCV infection (74% HCV seronegative 
IDUs versus 44% IDUs with chronic infection). Previous attempts to explain the 
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protective effect of KIR2DL3 and HLA-C1 homozygosity in viral infection argued 
towards a weaker interaction between KIR2DL3 and HLA-C1 compared to KIR2DL1 
HLA-C2 interaction (Hiby et al. 2004; Khakoo et al. 2004; Parham 2004), resulting in 
less KIR2DL3 mediated inhibition and easier activation of KIR2DL3+ NK cells 
Consistent with this notion, Winter et al. showed weaker binding between KIR2DL3-
Fc fusion proteins and HLA-C1 transfectants compared to KIR2DL1-Fc fusion 
proteins and HLA-C2 transfectants (Winter et al. 1998). However, direct 
measurements by surface plasmon resonance revealed almost similar affinity 
between KIR2DL3 and HLA-C1 and KIR2DL1 and HLA-C2, respectively (Vales-
Gomez et al. 1998; Maenaka et al. 1999). A study by Ahlenstiel et at. Described 
earlier and increased production of CD107a and IFN-γ by NK cells of KIR2DL3 HLA-
C1 homozygous patients in response to influenza A virus infected monocytes 
(Ahlenstiel et al. 2008), demonstrating increased antiviral functions of NK cells of 
KIR2DL3 HLA-C1 homozygous patients. However, the question why these cells are 
more active remained unanswered. 
 
Several receptors have been reported to be differentially expressed in HCV infection 
(reviewed in (Cheent et al. 2011)), however, the most consistent finding links 
increased frequencies of NKG2A+ NK cells to chronic HCV infection (Jinushi et al. 
2004; Nattermann et al. 2005; Nattermann et al. 2006; De Maria et al. 2007; 
Ahlenstiel et al. 2010). Here we confirmed this finding and, more importantly, report 
that NK cells of seronegative IDUs are characterized by low frequencies of NKG2A+ 
NK cells. The simultaneous analysis of the expression of NKG2A and KIR2DL3 on 
the same cell revealed a distinct NK cell phenotype in seronegative IDUs possibly 
linking an expansion of KIR2DL3+NKG2A- NK cells to protection from HCV infection. 
In addition we observe the inverse phenotype characterized by an expansion of 
KIR2DL3-NKG2A+ NK cells in IDUs with chronic HCV infection. We also found an 
inverse correlation between the expression of NKG2A and KIR2DL3, NKG2A and 
NKG2C as well as a positive correlation between KIR2DL3 and NKG2C. As 
described above, seronegative IDUs displayed significantly increased levels of 
NKG2C+ NK cells when compared to NK cells of chronically HCV infected IDUs 
alone. Although seronegative IDUs did no longer display significantly increased levels 
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of NKG2C when IDUs with resolved infection and healthy controls were taken into 
account as well, we still observed a strong trend towards increased NKG2C levels on 
NK cells of seronegative IDUs and IDUs with resolved infection, emphasizing a 
potential role of the C-type lectin-like binding receptors, NKG2A and NKG2C, in 
protection from HCV infection. 
 
This notion is further strengthened by the upregulation of HLA-E, the NKG2A/NKG2C 
ligand, in liver biopsies of HCV infected patients and a direct correlation between viral 
load and HLA-E transcript levels that we report here. Interestingly, we did not 
observe an upregulation of HLA-E transcript levels in liver biopsies of HBV infected 
patients. As HCV induces a strong IFN-α response in the host while HBV does not, 
we hypothesized that HLA-E might be upregulated in an IFN-α dependent manner. 
While cytosolic viral RNA binds to RIG-I, which is believed to be the main sensor for 
HCV infection, TLR3 senses endosomal double stranded RNA (reviewed in (Horner 
et al. 2013)). Upon engagement it induces the activation of IRF3, ultimately causing 
the induction of type I interferons. We stimulated primary human hepatocytes with the 
TLR3 agonist poly I:C in vitro and observed upregulation of HLA-E transcript levels. 
HLA-E is stabilized at the cell surface by binding of a very restricted subset of 
peptides derived from the leader sequence peptides of other HLA class I molecules, 
thus increased HLA-E transcript levels alone do not necessarily result in increased 
HLA-E protein expression. However, we were able to induce HLA-E expression on 
primary human hepatocytes by direct IFN-α stimulation, suggesting that HLA-E is 
upregulated in the HCV infected liver in an IFN-α dependent manner, possibly 
resulting from sensing of double stranded RNA by TLR3.  
 
Upregulation of HLA-E in HCV infected livers has previously been reported 
(Nattermann et al. 2005). In fact, Nattermann et al. describe an HCV peptide (core35-
44) actively stabilizing HLA-E on host cells, confirming the importance of HLA-E in 
HCV infection. Cheent et al. recently showed that core35-44 not only stabilized HLA-E, 
but in the presence of HLA Class I leader peptides inhibits NK cells via NKG2A. The 
data also demonstrate that CD94 in the absence of NKG2A has a distinct specificity 
for HLA-E-peptide complexes. The combination of peptides that bind the 
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CD94/NKG2A heterodimer with those binding only CD94 results in a synergistic 
inhibition of NKG2A+ NK cells (Cheent et al. 2013). 
 
Here we propose a new model explaining the protective effect described for 
KIR2DL3. We suggest that KIR2DL3 itself might not be directly responsible for 
protection from HCV infection but rather serves as a marker for NKG2A and NKG2C 
expression. We tested the functionality of NK cells of seronegative IDUs and IDUs 
with chronic HCV infection in response to different NK cell target cell lines, mediating 
NK cell activation via NKG2D, NCRs or CD16 and found increased CD107a 
expression by NK cells of seronegative IDUs in response to 221 cells. However these 
models do not take the specific intrahepatic environmental changes during HCV 
infection into account, as HLA-E is not included in these systems. We therefore 
tested NK cell functionality in response to HLA-E expressing target cells and 
compared it to functionality in the absence of HLA-E. Total NK cells of healthy 
individuals were inhibited in the presence of HLA-E. A more detailed analysis of the 
different NK cell subsets revealed that KIR2DL3-NKG2A+ NK cells were inhibited in 
the presence of HLA-E, while KIR2DL3+NKG2A- NK cells were not inhibited by 
HLA-E. However, when NK cells of healthy individuals were sorted and the 
functionality of the NKG2A enriched and NKG2A depleted NK cell fraction in 
response to HLA-E expressing and non-HLA-E expressing target cells was analyzed, 
we did not observe significant HLA-E mediated inhibition in the different fractions. 
This might be due to insufficient purity of the NKG2A sorted fractions using the Stem 
Cells technologies Easysept system, lack of accessory cells or impairment of NKG2A 
functionality by the antibody used to sort NKG2A+ NK cells.  
 
When we stimulated PMBCs of chronically HCV infected IDUs and seronegative 
IDUs with normal target cells and HLA-E expressing target cells we observed NK cell 
inhibition by HLA-E in NK cells from chronically HCV infected IDUs but not 
seronegative IDUs, indicating that the functionality of NK cells of seronegative IDUs 
is not impaired in the presence of HLA-E.  
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Collectively, our data strongly suggest that HCV seronegative IDUs are 
immunologically distinct by their NK cell population and to some extent protected 
from developing chronic hepatitis C infection. The protective effect is unlikely to 
prevent HCV entry and early viral replication. In fact, our proposed mechanism 
requires upregulation of HLA-E in the liver, which is observed upon HCV infection 
and is probably stimulated by type I or type III interferon. In the chimpanzee model 
high levels of interferon stimulated gene expression were observed within 2 days 
after HCV infection (Bigger et al. 2001; Park et al. 2012) whereas adaptive immune 
responses were delayed and became detectable only after 6-8 weeks (Thimme et al. 
2002; Shin et al. 2011). In the setting of intrahepatic HLA-E upregulation, KIR2DL3-
NKG2A+ NK cells, predominantly found in chronically HCV infected individuals, are 
potently inhibited allowing ongoing HCV replication and infection (Figure 5.1), while 
KIR2DL3+NKG2A-NK cells, characteristically found in seronegative IDUs, can readily 
respond before seroconversion as they are not inhibited by HLA-E (Figure 5.2).  
 
 
 
Figure 5.1: KIR2DL3
-
NKG2A
+
 NK cells are unable to protect from HCV infection.  
HCV infection of hepatocytes leads to HLA-E upregulation. KIR2DL3
-
NKG2A
+
 NK cells are inhibited by HLA-E 
and do not kill infected hepatocytes resulting in viral replication and chronic HCV infection.  
 
We hypothesize that less inhibition of NK cells from HCV seronegative IDUs during 
the very early phase of infection allows the eradication of the first wave of HCV 
infected hepatocytes even before humoral immune responses are induced. Evidence 
for viral replication is supported by detection of CD8 T cell responses against non-
structural proteins in a subset of HCV seronegative IDUs (21.1%; data not shown). 
Inhibited NK cell
NKG2A
HCV infects hepatocyte.  HCV induced HLA-E 
upregulation.
KIR2DL3-NKG2A+ NK cells 
are inhibited by HLA-E 
and remain inactive.  
HCV infected spreads 
through out the liver.  
HCV virion
HLA-E
KIR2DL3
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Such T cell responses were previously reported in similar HCV exposed cohorts, 
however, in previous studies and also in our cohort the magnitude of these T cell 
responses was rather low compared to IDUs with spontaneously resolved HCV 
infection and are therefore unlikely to mediate the protective effect against HCV (Al-
Sherbiny et al. 2005; Thurairajah et al. 2008; Thurairajah et al. 2011; Cameron et al. 
2013). 
 
Figure 5.2: KIR2DL3
+
NKG2A
-
 NK cells kill HCV infected hepatocytes.  
HCV induced HLA-E upregulation on hepatocytes does not inhibit KIR2DL3
+
NKG3A
-
 NK cells. In addition they 
might be activated by interaction NKG2C and HLA-E. Infected hepatocytes are eliminated and HCV controlled 
before seroconversion.  
 
Superior functionality of NK cells of seronegative IDUs in HCV infection might further 
be mediated by increased NKG2C and NKp46 levels on NK cells of seronegative 
IDUs compared to IDUs with chronic HCV infection. Although seronegative IDUs did 
no longer display significantly increased levels of NKG2C when all groups were 
included, the trend towards increased NKG2C levels on NK cells of seronegative 
IDUs and IDUs with resolved infection was still striking. As NKG2C also binds to 
HLA-E, increased degranulation or IFN-γ production might be expected by NK cells 
of seronegative IDUs in the presence of HLA-E. However, we did not observe 
increased functionality in this setting but merely absence of inhibition. This might be 
explained by the fact, that the affinity of HLA-E interaction is influenced by the bound 
peptide and is higher for NKG2A than NKG2C (Aldrich et al. 1994; Borrego et al. 
1998). Although NKG2C on NK cells of seronegtive IDUs does not activate NK cells 
in the presence of HLA-E, it might still help to overcome the inhibiting signals 
mediated by NKG2A molecules on the same cell.  
Activated NK cell
HCV virion
HLA-E
NKG2C
KIR2DL3
HCV infects hepatocyte.  HCV induced HLA-E 
upregulation.
KIR2DL3+NKG2A- NK cells 
are not inhibited by HLA-E 
and get activated.  
HCV infected hepatocytes
are killed preventing HCV 
infection from spreading.
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NK cells maturate from CD56bright to CD56dim NK cells. This maturation process is 
associated with dynamic changes in the expression patterns of NK cell receptors. 
NKG2A is expressed on approximately 90% of CD56bright NK cells and is lost when 
NK cells differentiate to CD56dim NK cells. This loss of NKG2A is accompanied by 
acquisition of KIRs, NKG2C and CD57 as a marker for previously activated NK cells 
(Bjorkstrom et al. 2010; Lopez-Verges et al. 2010). Although the phenotype of the NK 
cells of seronegative IDUs resembles the phenotype of a mature NK cell, we did not 
find clear evidence that the elevated frequencies of KIR2DL3+NKG2A- NK cells in 
HCV seronegative IDUs are the consequence of an advanced differentiation state, as 
there was no statistically significant difference in subset distribution and CD57 
expression. It seems plausible that the NK cell phenotype in this subgroup of IDUs is 
predominantly the result of differential NK cell licensing/education and is determined 
by genetic predisposition. For successful arming NK cells need to be licensed by 
ligation of KIRs with the relevant ligand. Studies in humans indicate that the 
genetically determined KIR/KIR-ligand combination impacts NK cell education and 
the functional responsiveness (Yawata et al. 2008; Schonberg et al. 2011). 
Expression of NKG2A was found to buffer the overall functional responses in KIR 
repertoires (Andersson et al. 2009). This is in line with the observation that the 
phenotype protective against HCV is associated with a distinct KIR/KIR-ligand 
genotype (Khakoo et al. 2004; Knapp et al. 2010; Knapp et al. 2011). Of note, there 
was a trend towards increased frequencies of CD57 expressing NK cells in the 
CD56dim population of seronegative IDUs and IDUs with resolved HCV infection, 
indicating that an advanced differentiation state of NK cells may at least partly 
contribute to the phenotype. To address this conclusively larger cohorts need to be 
studied. 
 
We included HCV seronegative IDUs from the ward for inpatient detoxification 
treatment of drug addicts as well as from the clinic for opiate substitution treatment. 
Given an HCV seroprevalence in IDUs from Germany of more than 80% and based 
on the reported risk behavior of this patient population (Scherbaum et al. 2009), 
exposures to HCV are likely to have occurred also in the HCV seronegative group. 
Due to the cross-sectional design of our study we were unable to analyze samples 
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from HCV-RNA positive IDUs prior to seroconversion. Importantly, our data suggest 
that the difference in NK cell phenotype is not simply the consequence of HCV 
infection or injection drug use as healthy controls showed an NK cell phenotype 
similar to IDUs with chronic infection. In previous studies different factors have been 
associated with HCV infection status in IDUs including age, duration of injection drug 
use and time in prison. This strongly suggests that the likelihood and frequency of 
exposures to HCV is an important factor that predicts the infection status. We also 
noted shorter duration of injection drug use in HCV seronegative IDUs (table 2.1). 
Although we cannot formally prove that HCV seronegative IDUs were indeed 
exposed to HCV, our data and previous studies support that the subgroup of 
seronegative IDUs is also biologically distinct and not solely the product of a different 
risk taking behavior (Golden-Mason et al. 2010; Knapp et al. 2010; Knapp et al. 
2011; Warshow et al. 2012). The protective effect of the KIR2DL3+NKG2A- NK cell 
population in HCV seronegative IDUs may not be absolute and the behavioral risk 
profile clearly contributes to the HCV infection status. It seems possible that the NK 
cell phenotype described here is beneficial upon exposures to low doses of HCV as it 
might be more common during needle sharing. This would be in line with previous 
genetic association status reporting a protective effect of homozygosity for the 
KIR2DL3 gene allele and its ligand HLA-C1 only in patients exposed to HCV by IDU 
but not in patients who received blood transfusion (Khakoo et al. 2004). In case of 
exposure to higher concentrations of HCV the protective effect may be overcome 
followed by acute hepatitis C.  
5.2 NK cell memory, HCVM infection status and HCV infection outcome 
Previously, mature NK cells in the periphery were considered a terminally 
differentiated effector cell population incapable of self-renewal. If a mature NK cell 
became activated and performed its effector duties, it was also thought to die within a 
half-life of approximately 2 weeks (Jamieson et al. 2004). This dogma has recently 
been challenged by several studies demonstrating that a long lived subset of 
previously activated NK cells exits (Pyzik et al. 2009; Paust et al. 2010; Sun et al. 
2011; Abdul-Careem et al. 2012). Most prominently HCMV, a complex beta herpes 
virus capable of replicating in various cell types, has been reported to induce a long 
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lasting reconfiguration of the NK cell subset, characterized by expansion of NK cells 
expressing high levels of NKG2C (Guma et al. 2004). These NKG2C+ NK cells are 
also characterized by low expression levels of NKG2A, NKp30 and NKp46 as well as 
increased expression of LILRP1 and KIRs (Muntasell et al. 2013). In addition Beziat 
et al. reported that HCMV seropositivity is associated with an expansion of 
CD56dimNKG2C+ NK cells in patients with chronic HBV or HCV infection. Multi-color 
flow cytometry revealed that the expanded CD56dimNKG2C+ NK cells displayed a 
highly differentiated phenotype, expressed high amounts of granzyme B and 
exhibited polyfunctional responses (CD107a, IFN-γ, and TNF-α) to stimulation with 
antibody-coated as well as HLA-E expressing target cells but not when stimulated 
with IL-12/IL-18. Importantly, CD56dimNKG2C+ NK cells had a clonal expression 
pattern of inhibitory KIR receptors specific for self-HLA class I molecules, with 
predominant usage of KIR2DL2/3 (Beziat et al. 2012). 
 
Taken together, the NK cell phenotype induced in HCVM infection closely resembles 
the NK cell phenotype we describe as protective in HCV infection, suggesting a 
possible association between HCV infection outcome and HCMV infection status. To 
address this, we determined the CMV serostatus of 391 IDUs from our cohort. Our 
analysis revealed that 52% of IDUs chronically infected with HCV were seropositive 
for HCMV while 60% of IDUs with resolved and 59% of HCV seronegative IDUs were 
tested positive for anti-CMV. Although this difference is clearly not statistically 
significant, there is the expected tendency linking HCMV infection to HCV clearance 
and resistance. The relevance of this trend of higher CMV seroprevalence in IDUs 
protected from HCV infection is further strengthened when the age of IDUs is taken 
into account. The HCMV prevalence typically increases with age (Lubeck et al. 
2010), however, our cohort of seronegative IDUs are in average significantly younger 
than chronically HCV infected IDUs. Moreover, we observed differences in the 
median time of drug consumption between the groups with different HCV infection 
outcome. Patients chronically infected with HCV report a median time of drug abuse 
of 15.3 years while IDUs with resolved HCV infection and seronegative IDUs report 
median times of drug abuse of 8.6 years and 6.7 years. To our knowledge there is no 
specific data on the HCMV seroprevalence in IDUs in Germany or a study linking 
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HCMV prevalence to duration of drug abuse. However, we would expect HCMV 
prevalence to increase with time of drug abuse. The patients included in this analysis 
were chosen based solely on their HCV infection status, however multiple factors are 
known to influence HCV infection outcome, including IFNL3 genotype (Tillmann et al. 
2010), KIR2DL3 genotype (Khakoo et al. 2004; Knapp et al. 2010) and gender (Page 
et al. 2009). Further stratification of the included subjects with respect to known 
protective factors such as IFNL3 or KIR2DL3 genotype might give better insights into 
the interplay between HCV and HCMV infection. In addition a renewed expansion of 
NKG2C+ NK cells has been reported to be likely in reactivation of HCMV infection 
(Guma et al. 2006) suggesting a possible link between the time point of HCMV 
infection and HCV clearance.  
 
In summary, KIR2DL3+NKG2A- NK cells are conclusively linked to favorable HCV 
infection outcome. Our data indicates that there might be more than one path to the 
generation of this favorable NK cell phenotype. While some patients have the 
KIR2DL3+NKG2A- NK cell phenotype by genetic predisposition mediated by KIR2DL3 
and HLA-C1 group alleles others may develop it as a result of encountering infections 
such as HCMV throughout their live. A prospective study analyzing potential changes 
of the NK cell phenotypes, HCV infection status and HCMV infection status over a 
longer period of time is needed and would allow to gain new insights into the 
dynamics of the interaction between NK cells and HCV infection. 
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6 Summary 
Intravenous drug users (IDUs) are a major risk group for hepatitis C infection in 
Germany. In fact 73% of IDUs living in Germany are HCV seropositive while only 
27% of IDUs are HCV seronegative. The frequently reported shared use of injection 
equipment suggests that the majority of HCV seronegative IDUs have also been 
exposed to HCV, raising the question why these IDUs do not seroconvert and if they 
might have some kind of natural resistance to HCV infection. NK cells represent a 
major subset of intrahepatic lymphocytes and certain NK cell phenotypes have been 
associated with HCV infection outcome. NK cells are regulated by a complex network 
of activating and inhibiting receptors. Interestingly, homozygosity for the inhibiting NK 
cell receptor gene KIR2DL3 and its ligand HLA-C1 has been associated with HCV 
clearance and resistance to HCV. However, the functional mechanisms underlying 
this protective effect by genetic predisposition remain elusive.  
 
In this study we comparatively analyzed the phenotype and function of NK cells of 
IDUs with chronic HCV infection, resolved HCV infection and seronegative IDUs. Our 
results show that NK cells of seronegative IDUs are characterized by higher 
frequencies of NKp46, KIR2DL3 and NKG2C and lower frequencies of NKG2A. In 
line with a functional benefit of higher NKp46 expression levels, we observed 
increased CD107a production by NK cells of seronegative IDUs when NK cells were 
activated via NKp44 and NKp46. A more detailed analysis of NKG2A and KIR2DL3 
revealed significantly higher frequencies of KIR2DL3+NKG2A- NK cells in HCV 
seronegative IDUs. In addition, we showed an inverse correlation between KIR2DL3 
and NKG2A expression, suggesting that KIR2DL3 may potentially serve as a tag for 
NKG2A expression rather than playing a causal role for the previously described 
protective effects itself. Analysis of liver biopsy samples revealed increased 
transcription levels of HLA-E, the NKG2A ligand, in liver biopsies of HCV infected 
patients correlating with HCV viral load. In vitro experiments with primary human 
hepatocytes demonstrated that HLA-E transcription and protein expression were 
upregulated by IFN-α. To elucidate the influence of HLA-E on the KIR2DL3+NKG2A- 
NK cells of seronegative IDUs, we stimulated NK cells of healthy individuals with 
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HLA-E high and low expressing target cells and analyzed CD107a and IFN-γ 
production. Total NK cells and KIR2DL3-NKG2A+ NK cells were inhibited in the 
presence of HLA-E high expressing target cells, while KIR2DL3+NKG2A- NK cells 
were not inhibited in the presence of HLA-E. Furthermore, we were able to show that 
NK cells of chronically HCV infected IDUs were potently inhibited in the presence of 
HLA-E while NK cells of seronegative IDUs showed no inhibition. We suggest a 
model in which HCV productively infects hepatocytes and causes type I interferon-
mediated HLA-E upregulation. In this setting KIR2DL3-NKG2A+ NK cells, 
predominantly found in chronically HCV infected individuals, are potently inhibited by 
HLA-E allowing ongoing HCV replication and persistent infection, while 
KIR2DL3+NKG2A- NK cells, characteristically found in seronegative patients, can 
readily respond and eliminate HCV infection before seroconversion. 
 
Expansion of this “protective” NK cell phenotype in HCV seronegative IDUs could be 
the consequence of distinct NK cell education/licensing or a different NK cell 
differentiation stage. In favor of distinct education of NK cells in HCV seronegative 
IDUs we did not observe a statistically significant difference in CD57 expression as a 
marker of advanced differentiation of NK cells. This would be in line with previous 
genetic association studies linking a particular KIR/KIR-ligand genotype with 
favorable HCV outcome. However, there was at least a trend towards higher CD57 
expression on NK cells of HCV seronegative IDUs, suggesting that an advanced 
differentiation state my partly contribute to the phenotype. Interestingly, the NK cell 
phenotype in HCV seronegative IDUs resembles the NK cell phenotype described 
upon HCMV infection. Collectively, our data indicate that there might be more than 
one path to the generation of the favorable KIR2DL3+NKG2A- NK cell phenotype. 
While some patients have the NK cell phenotype by genetic predisposition others 
may develop it as a consequence of infections such as HCMV. A prospective study 
analyzing potential changes of the NK cell phenotypes, HCV infection status and 
HCMV infection status over a longer period of time is needed and would allow to gain 
new insights into the dynamics of the interaction between NK cells and HCV 
infection. 
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7 Zusammenfassung 
Patienten mit intravenösem Drogenabusus („intravenous drug users“, IDUs) stellen 
eine Hauptrisikogruppe für Hepatitis-C-Virusinfektionen in Deutschland dar. In 
Deutschland sind 73% aller IDUs HCV seropositiv und nur 27% HCV seronegativ. Da 
Injektionsutensilien häufig von mehreren Personen geteilt werden, sind mit hoher 
Wahrscheinlichkeit nahezu alle IDUs einschließlich der seronegativen Patienten HCV 
exponiert. Dies wirft die Frage auf, warum diese Gruppe der IDUs keine akute 
Infektion entwickelt und ob sie eine Art „natürliche Resistenz“ gegen eine HCV-
Infektion haben.  
 
NK-Zellen sind eine wichtige Population intrahepatischer Lymphozyten und 
unterschiedliche NK-Zellphänotypen wurden bei unterschiedlichen HCV-
Infektionsverläufen beschrieben. NK-Zellen werden durch ein komplexes Netzwerk 
aus aktivierenden und inhibierenden Rezeptoren reguliert. Patienten, die für das Gen 
des inhibierenden NK-Zellrezeptors KIR2DL3 und seinen Liganden HLA-C1 
homozygot sind, haben eine erhöhte Wahrscheinlichkeit, eine HCV-Infektion spontan 
auszuheilen oder erst gar nicht infiziert zu werden. Allerdings bleibt der funktionelle 
Mechanismus für diesen protektiven Effekt ungeklärt. 
 
In dieser Studie haben wir den Phänotyp und die Funktion der NK-Zellen von IDUs 
mit chronischer HCV-Infektion, ausgeheilter HCV-Infektion und HCV seronegativen 
IDUs vergleichend analysiert. Unsere Ergebnisse zeigen, dass die NK-Zellen HCV 
seronegativer IDUs durch höhere Frequenzen von NKp46, KIR2DL3 und NKG2C 
sowie einer niedrigeren Frequenz von NKG2A charakterisiert sind. In Einklang mit 
der erhöhten NKp46 Frequenz wiesen NK-Zellen von HCV seronegtiven IDUs einen 
funktionellen Vorteil durch erhöhte CD107a Produktion auf, wenn sie über NKp44 
und NKp46 stimuliert wurden. Eine detaillierte Analyse von NKG2A und KIR2DL3 
zeigte statistisch signifikant erhöhte Frequenzen von KIR2DL3+NKG2A- NK Zellen 
bei HCV seronegativen IDUs. Zusätzlich konnten wir eine inverse Korrelation 
zwischen der Expression von KIR2DL3 und NKG2A zeigen. Es erscheint daher 
möglich, dass  KIR2DL3 lediglich als Marker für eine niedrige NKG2A-Expression 
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fungiert und selbst gar nicht für den ihm zugeschrieben protektiven Effekt 
verantwortlich ist. Die Analyse von Leberbiopsien HCV-infizierter Patienten zeigte 
eine erhöhte Transkription des NKG2A-Liganden HLA-E sowie eine Korrelation mit 
der Höhe der Viruslast. In primären humanen Hepatozyten wurde sowohl die HLA-E 
Transkription als auch die Proteinexpression durch Stimulation mit IFN-α erhöht. Um 
den Einfluss von HLA-E auf die KIR2DL3+NKG2A- NK-Zellen seronegativer IDUs 
weiter zu untersuchen, wurden NK-Zellen gesunder Individuen mit aktivierenden 
Zellen stimuliert, die entweder eine hohe oder eine niedrige HLA-E-Expression 
aufwiesen. In der Analyse von CD107a und IFN-γ Expression zeigte sich, dass die 
Gesamtpopulation der NK-Zellen sowie die Teilpopulation der KIR2DL3-NKG2A+ NK- 
Zellen in Anwesenheit von HLA-E inhibiert werden. Im Gegensatz dazu wurden die 
KIR2DL3+NKG2A- NK-Zellen nicht durch HLA-E inhibiert. Weiterhin konnten wir 
zeigen, dass NK-Zellen von chronisch mit dem HCV infizierten IDUs aber nicht NK-
Zellen von HCV seronegativen IDUs wirksam durch die Anwesenheit von HLA-E 
inhibiert wurden. Wir schlagen hier ein Modell vor, in dem das HCV Hepatozyten 
infiziert und über Induktion von Typ I Interferonen HLA-E auf Hepatozyten 
hochreguliert. In diesem System werden KIR2DL3-NKG2A+ NK-Zellen, die 
vorwiegend in chronisch infizierten Patienten gefunden werden, effizient durch HLA-E 
gehemmt, was eine weitere HCV Replikation  ermöglicht und in einer persistierenden 
Infektion resultiert. Im Gegensatz dazu können KIR2DL3+NKG2A- NK-Zellen der 
HCV seronegativen IDUs aktiviert werden und die Infektion kontrollieren, bevor es 
zur Serokonversion kommt.   
 
Die Expansion dieser „protektiven“ NK-Zellen könnte die Folge einer speziellen  NK-
Zell-Lizensierung oder einer veränderten Differenzierung sein. Für die spezielle 
Lizensierung spricht, dass wir keine statistisch signifikanten Unterschiede bei dem 
Differenzierungsmarker CD57 feststellen konnten. Die spezielle Lizensierung wäre 
auch im Einklang mit der genetischen Assoziation zwischen bestimmten KIR/KIR-
Liganden-Kombinationen und einem vorteilhaften HCV-Infektionsverlauf. Allerdings 
war zumindest eine Tendenz zu erhöhter Expression von CD57 auf NK-Zellen von 
seronegativen IDUs erkennbar, so dass ein fortgeschrittener Differenzierungsgrad 
der NK-Zellen zum „protektiven“ Phänotyp beitragen könnte. Interessanterweise 
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ähnelt der NK-Zellphänotyp der HCV seronegativen IDUs dem Phänotyp nach einer 
HCMV Infektion. Zusammengefasst, weisen unseren Daten darauf hin, dass es mehr 
als einen Weg zu dem günstigen KIR2DL3+NKGA- NK Zell Phänotyp geben könnte. 
Während einige Patienten diesen Phänotyp als Konsequenz ihrer Immungenetik 
haben, resultiert er bei anderen möglicherweise aus einer Infektion zum Beispiel mit 
CMV. Eine Studie, die die Dynamik des NK-Zell-Phänotyps, sowie den HCV- und 
HCMV-Infektionsstatus über einen längeren Zeitraum untersucht, würde neue 
Einsichten in die Rolle von NK-Zellen bei der HCV-Infektion ermöglichen.    
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